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Protein S-palmitoylation is a reversible post-translational lipid modification that regulates 
the trafficking, stability, and activity of proteins in eukaryotes. The detection of fatty-
acylated proteins has been challenging but recent advances in chemical labeling methods 
have enabled more sensitive detection and proteomic analyses, which I summarize in 
Chapter 1. The proteomic analysis of S-palmitoylated proteins in dendritic cells and 
macrophages by our laboratory revealed that the interferon-induced transmembrane 
proteins (IFITMs) are S-fatty-acylated at conserved cysteine (Cys) residues. IFITMs are 
unique interferon-induced proteins that restrict the infection of multiple pathogenic viruses. 
Initial studies by our laboratory showed that S-fatty-acylation on three conserved Cys 
residues were crucial for IFITM3 anti-influenza virus activity. However, endogenous 
levels and site-specific functions of S-palmitoylation on the individual IFITM3 Cys 
residues were unknown and are addressed in Chapter 2. In collaboration with other 
members of the Hang laboratory, we discovered that endogenous IFITM3 is fully S-fatty-
acylated in IFN-stimulated mammalian cells and that Cys72 in particular plays an 
important role in IFITM3 antiviral activity. My additional biochemical studies suggest S-
palmitoylation may regulate IFITM3 protein turnover in mammalian cells. 
 IFITMs appear to inhibit virus entry into mammalian cells, but the precise 
mechanisms have been unclear due to limited methods for live-cell imaging and IFITM3 
protein-protein interaction studies. To address these limitations, I explored amber codon 
suppression technology for site-specific IFITM3 labeling with unnatural amino acids for 
bioorthogonal imaging and covalent protein crosslinking in mammalian cells in Chapter 3. 
Using the pyrrolysyl-tRNA synthetase (PylRS)/Pyl tRNACUA system, I showed that 
unnatural amino acid can be site-specifically incorporated throughout IFITM3 in 
mammalian cells. The site-specific labeling of IFITM3 with unnatural amino acids has 
provided new opportunities for live-cell imaging and photocrosslinking studies with 
specific interacting proteins in Chapter 4. My thesis studies have revealed additional insight 
into IFITM3 regulation by S-palmitoylation and established new tools to explore the 
antiviral mechanism of IFITMs. 
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Chapter One: Biochemical methods for analyzing protein fatty-
acylation  
1.1 Introduction to protein fatty-acylation 
Of the numerous protein modifications in bacteria and eukaryotes (Walsh et al., 
2005), lipidation is especially intriguing due to its ability to directly regulate protein 
hydrophobicity and membrane trafficking. Lipidation refers to the covalent attachment of 
lipid or lipid-like groups onto proteins (Hang and Linder, 2011; Resh, 2006). Fatty-
acylation and prenylation are the most common types of protein lipidation found in 
mammalian cells (Hang and Linder, 2011; Resh, 2006). While prenylation primarily occurs 
at the C-terminus of proteins through a thioether bond, protein fatty-acylation can be 
attached through S-, O-, or N-linkages at different sites throughout proteins. Protein fatty-
acylation occurs co- or post-translationally and plays an essential role in regulating protein 
function and localization. Specifically, during the protein modification, lipid moieties with 
varying chain length, such as myristate (14 carbons) and palmitate (16 carbons), covalently 
attach to proteins under the regulation of a set of enzymes like acyltransferases and 
deacylases. Furthermore, lipidated proteins can have distinct interactions with signaling 
proteins and specific membrane domains. In this introduction, we will focus on protein 
fatty-acylation and will present a summary of chemical tools used for detecting these 
modifications in vitro and in vivo. 
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Figure 1. Different types of fatty-acylated proteins A) S-palmitoylation. B) N-
myristoylation. C) N-palmitoylation. D) Stearoylation. E) Palmitoleylation on Ser or Thr. 
F) Lys-myristoylation. 
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Figure 2. Function of protein fatty-acylation. Protein fatty-acylation regulates the 
interaction of the modified proteins with cellular membrane. The presence or absence of 
fatty-acylation also regulates protein stability, degradation and complex formation. 
Specific fatty-acylation might determine the cellular microdomain targeting and cellular 
vesicle shuttle. 
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1.1.1 S-fatty-acylation 
Protein S-fatty-acylation, or frequently referred to as S-palmitoylation, is the post-
translational modification of fatty acids onto Cys residues via a thioester linkage 
(Chamberlain and Shipston, 2015) (Figure 1A). S-palmitoylation is often used to describe 
this modification because palmitate is the predominant fatty acid in this process. However, 
other long chain fatty acids have also been observed (Liang et al., 2001). Protein S-
palmitoylation was first documented more than 30 years ago (Schmidt and Schlesinger, 
1979), but the enzymes responsible for this modification took over 20 years to identify 
(Bartels et al., 1999; Deschenes and Broach, 1987). Historically, radioactive labeling using 
[3H]palmitate had been the major method to study palmitoylation. G protein-coupled 
receptors (GPCR) (O’Brien and Zatz, 1984), Gα subunits (Linder et al., 1993), Src family 
kinases (Paige et al., 1993), Ras proteins (Buss and Sefton, 1986), and soluble N-
ethylmaleimide-sensitive factor attachment protein receptor (SNARE) (Hess et al., 1992) 
are among the list of proteins that were identified using this approach. S-fatty-acylation is 
enzymatically mediated by a family of zinc finger DHHC (zDHHC) motif-containing 
protein acyltransferases (DHHC-PATs) that catalyze S-palmitoylation. There are seven 
DHHC proteins in budding yeast (Mitchell et al., 2006), five in fission yeast (Zhang et al., 
2013a) and more than 20 DHHC genes in mammalian species, all of which are multi-pass 
transmembrane proteins. Early work on DHHC enzymatic activity towards postsynaptic 
density protein of 95 kDa (PSD-95), which was the first comprehensive analysis of the 
mammalian DHHC, identified that DHHC 2, 3, 7 and 15 were the most active (Fukata et 
al., 2004). 
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Protein S-fatty-acylation is a reversible process, a key property that distinguishes it 
from other lipid modifications. Pulse-chase experiments on N-Ras with [3H] palmitate 
highlighted the reversibility of S-fatty-acylation (half-life ~20 min) (Magee et al., 1987). 
That deacylation of N-Ras may occur 10–20 times faster than calculated by pulse-chase 
analysis (Rocks et al., 2005, 2010). However, marked differences can exist in the turnover 
rates of different S-fatty-acylation sites in the same protein (Zuckerman et al., 2011). 
Indeed, rates of palmitate turnover at each cysteines are dramatically different. For example, 
although S-palmitoylation at the proximal site of the β-adrenergic receptor is remarkably 
stable, S-palmitoylation at the distal site is rapidly turned over. Thus, the dynamics of 
acylation/deacylation is an outstanding question in the S-fatty-acylation research: how the 
dynamics of lipid turnover of S-fatty-acylated proteins is regulated and why different 
proteins display distinct turnover rates. Notably, recent enrichment and mass-
spectrometry-based proteomics approaches have significantly accelerated the 
characterization of S-fatty-acylated proteins and reignited the interest in the poorly 
characterized dynamics of protein S-fatty-acylation (Peng et al., 2016; Zhou et al., 2014). 
Major functions of protein S-fatty-acylation include targeting proteins to discrete 
intracellular membrane compartments, control of protein stability and modulation of 
protein-protein interactions (Chamberlain and Shipston, 2015) (Figure 2). Furthermore, the 
reversibility of S-fatty-acylation offers spatial and temporal control of protein function, for 
example, stable association, and release of peripheral membrane proteins from lipid 
bilayers (Figure 3).  
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Figure 3. Protein S-fatty-acylation regulates multiple steps in the life cycle of 
membrane and peripheral membrane proteins. Protein S-fatty-acylation can happen at 
multiple locations including ER, Golgi, endosomes, as well as the plasma membrane. A) 
Protein synthesis and ER exit. B) Maturation and Golgi exit. C) Sorting and trafficking to 
the plasma membrane. D) Clustering into membrane microdomains. E) Partitioning of 
peripheral membrane proteins between the cytosol and membranes. F) Internalization. G) 
Recycling and degradation. 
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1.1.2 N-myristoylation 
Protein N-myristoylation describes the covalent modification of N-terminal Gly residues 
with a 14 carbon fatty acid (myristate) (Farazi et al., 2001) (Figure 1B). This fatty acid is 
transferred from myristoyl-CoA to substrate proteins by N-myristoyltransferase (NMT). 
N-myristoylation is necessarily preceded by proteolysis to reveal an N-terminal glycine, 
the only completely conserved motif across all known NMT substrates. N-myristoylation 
can also occur posttranslationally during apoptosis upon proteolytic cleavage, thereby 
exposing an N-terminal glycine residue within a myristoylation consensus sequence 
(Martin et al., 2011). Recent chemical proteomics approaches identified N-myristoylated 
proteins during normal cellular growth and apoptosis (Martin et al., 2008; Thinon et al., 
2014). The wide scope of substrates with diverse functions that undergo co-translational or 
post-translational N-myristoylation, such as c-Abl (Nagar et al., 2003), c-Src (Patwardhan 
and Resh, 2010), Bid (Zha et al., 2000), PAK2 (Vilas et al., 2006), and gelsolin (Sakurai 
and Utsumi, 2006), to name a few, underscores the critical role that N-myristoylation plays 
not only in proper localization of proteins but also regulating their activity. Notably, atomic 
crystal structures of c-Abl show that the N-terminal myristoyl modification of c-Abl 1b 
binds to the kinase domain and induces conformational changes that allow the SH2 and 
SH3 domains to dock onto it (Nagar et al., 2003). These approaches should help uncover 
potential roles of N-myristoylation in cancer and neurodegenerative disease.  
The 50-60 kDa monomeric enzyme NMT catalyzes the transfer of myristate from 
myristoyl-CoA to suitable peptides and proteins. The structure of the yeast Saccharomyces 
cerevisiae NMT1p was solved as a ternary complex and reveals how myristoyl-CoA and 
peptide substrates bind to the enzyme (Bhatnagar et al., 1998). Although usually non-
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eukaryotic species lack NMT that is required for this modification, there are instances of 
pathogen-host interaction around N-myristoylation. Indeed, since first discovered in the 
early eighties, many viral proteins has been found to be myristoylated by NMTs of their 
eukaryotic hosts (Maurer-Stroh and Eisenhaber, 2004). N-myristoylation of viral proteins 
has roles in assembly, structure, budding, viral entry and intracellular host interactions. 
Furthermore, bacteria effectors injected into host cells through type III secretion system 
(TTSS) can also be myristoylated (Nimchuk et al., 2000). A recent study found that 
Shigella flexneri virulence factor invasion plasmid antigen J (IpaJ) cleaves N-myristoylated 
glycines of eukaryotic proteins as a pathogenic mechanism in host cells (Burnaevskiy et 
al., 2013, 2015). Specifically, mass spectrometry showed that IpaJ cleaved the peptide bond 
between N-myristoylated Gly2 and Asn3 of human ARF1, thereby providing a new 
mechanism for host secretory inhibition by a bacterial pathogen (Burnaevskiy et al., 2013, 
2015). 
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1.1.3 O-acylation 
Protein O-acylation is a less common form of fatty-acylation at serine or threonine residues. 
A notable example of O-acylation is O-palmitoleoylation on Wnt proteins (Figure 1E). 
Wnts are secreted signaling molecules that are covalently modified with palmitoleic acid 
(16:1) at a serine residue (Gao and Hannoush, 2014; Takada et al., 2006). Other O-acylated 
proteins include ghrelin (Gutierrez et al., 2008; Yang et al., 2008), PLTX-II (Branton et al., 
1993), and histone H4 protein (Zou et al., 2011). Serine-3 of ghrelin is acylated with an 
eight-carbon fatty acid, octanoate, which is required for its endocrine actions. Notably, Wnt 
has been studied extensively because first of all, Wnt protein family is one of the largest 
secreted protein families that are responsible for extracellular signaling in virtually all 
animal development stages, and secondly post-translational fatty acylation is essential for 
its activity. Interestingly, mass spectrometry studies and recent bioorthogonal fatty acid 
labeling on Wnt3a have shown that Ser209 is O-palmitoleoylated rather than Cys77 (Gao 
and Hannoush, 2014; Takada et al., 2006). The enzyme that is responsible for the 
modification is called Porcupine, a member of membrane-bound O-acyl transferase 
(MBOAT). Chemical reporter methods also demonstrated that Porcupine is S-
palmitoylated, which negatively regulates Wnt signaling (Berthiaume, 2014). 
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1.1.4 ε-N-Lys acylation 
Fatty-acylation on Lys side-chain via formation of an amide bond is another potentially 
regulated lipid modification (Figure 1F). Tumor necrosis factor alpha (TNF-α) precursor 
and Interleukin-1-α were shown to undergo myristoylation on specific inner lysine residues 
(Stevenson et al., 1992, 1993). ε-N-Ly acylation has been long thought to be non-
hydrolysable due to the irreversible nature of amide bond linkage, but the recent discovery 
of SIRT6, a sirtuin family NAD+-dependent protein deacetylase that can also remove long-
chain fatty acids on Lys side chains reignites interests on dynamics regulation of fatty N-
acylation. SIRT6 promotes the secretion of TNF-α by removing the fatty acyl modification 
on K19 and K20 of TNF-α (Jiang et al., 2013). Subsequently, in vitro studies of all sirtuins 
to hydrolyze 13 different acyl groups have revealed the specificity of sirtuin enzymes for 
deacylating Lys modified with a broad range of fatty acids (Feldman et al., 2013; Teng et 
al., 2015). Interestingly, free fatty acids (FFAs) could stimulate deacetylation activity of 
SIRT6 towards long-chain acylated peptides. Crystal structure of SIRT6 reveals that, 
different from the other four members of mammalian sirtuins family, there is a large 
hydrophobic pocket that can accommodate long-chain fatty acyl groups rather than shorter 
acetyl groups. The new findings of protein deacylation enzyme activity provide a roadmap 
to uncover the biological functions of protein ε-N-Lys-fatty-acylation modifications with 
previously unknown functions.  
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1.2 Methods for analyzing fatty-acylated proteins 
Due to the importance of protein fatty-acylation in regulating protein function, there have 
been significant interests in detecting and characterizing these modifications in cells. 
Unlike phosphorylation and other post-translational modifications, no robust antibodies 
specific to lipid-modified peptides or proteins are readily available. Bioinfomatic 
predictions of fatty-acylation are also limited since some modifications do not have clear 
consensus motifs (Table 1). Traditionally, the analysis of protein fatty-acylation relied on 
radioactive lipid labeling, followed by immune precipitation and lengthy film exposure 
(Berthiaume et al., 1995; Schlesinger et al., 1980). However, this classical method suffers 
the risks associated with radioactivity, as well as low sensitivity and long exposure time, 
from days to months. Other methods like acyl-biotin exchange (ABE) (Drisdel and Green, 
2004) and acyl-resin-assisted capture (acyl-RAC) (Forrester et al., 2011) are useful to 
detect and enrich S-acylated proteins since the thioester bond can be readily cleaved with 
hydroxylamine and replaced by other functional groups. 
Bioorthogonal chemistry developed in the recent years has permitted improved 
detection and large-scale proteomic analysis of fatty-acylated proteins (Hang and Linder, 
2011; Hang et al., 2011). The two-step strategy involves metabolic labeling with chemical 
reporters and then detection using bioorthogonal chemistry (Grammel and Hang, 2013; 
Prescher and Bertozzi, 2005). The advantages of separating incorporation and detection are 
that 1) sterically-demanding fluorophores or affinity tags would not interfere with chemical 
reporter incorporation and 2) chemical reporters provide direct detection of the modified 
substrate.  
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Table 1. List of fatty acylation prediction sites. 
Myristoylation 
predictor  
http://mendel.imp.ac.at/myristate/ (Maurer-Stroh 
and Eisenhaber, 
2004) 
http://web.expasy.org/myristoylator/ (Bologna et al., 
2004) 
http://plantsp.genomics.purdue.edu/myrist.html (Podell and 
Gribskov, 2004) 
Palmitoylation 
predictor 
http://doc.aporc.org/wiki/CKSAAP-Palm (Wang et al., 
2009) 
http://csspalm.biocuckoo.org/ (Ren et al., 2008) 
http://nbapalm.biocuckoo.org/ (Xue et al., 2006) 
http://14.139.227.92/mkumar/palmpred/ (Kumari et al., 
2014) 
http://bioinfo.ncu.edu.cn/WAP-Palm.aspx (Shi et al., 2013) 
Prenylation site 
predictor 
http://mendel.imp.ac.at/sat/PrePS/ (Maurer-Stroh 
and Eisenhaber, 
2005) 
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1.2.1 Detection of fatty-acylation by radiolabeling 
The traditional method for detecting fatty-acylation study used radio-active 3H-, 14C-
labeled or iodinated fatty acids, which are converted into fatty-acyl-CoA in cells and 
incorporated into proteins. Compared to 3H-, 14C-labeling methods, use of radioiodinated 
fatty acids is advantageous, because it reduces the exposure times and allows the use of 
phosphorimager technology (Berthiaume et al., 1995; Peseckis et al., 1993). 
1.2.2 Bioorthogonal detection of fatty-acylation using chemical reporters 
By first incorporating fatty acid chemical reporters that contain bioorthogonal handles, we 
can then label modified proteins with secondary detection tags such as fluorophores or 
affinity tags (Charron et al., 2009a). The chemical reporter is usually of similar size with 
natural fatty acid (azide- or alkyne- reporter) to facilitate recognition by acyltransferase 
inside cells (Table 2). In vitro labeling can also be done using fatty acyl-CoA reporter 
analogs. Although both azide and alkyne reporters have been used in the past, alkyne 
reporters are preferred for detection of protein fatty-acylation due to its better efficiency 
and specificity (Figure 4) (Thinon and Hang, 2015). Our lab has successfully detected 
protein N-myristoylation (Charron et al., 2009a), S-palmitoylation (Charron et al., 2009a; 
Yount et al., 2010; Zhang et al., 2010), S-prenylation (Charron et al., 2011) and Lys-
acetylation (Yang et al., 2010b) using alkynyl-chemical reporters in the past. Alkyne-
tagged reporters have been used in specific and efficient two-step labeling with Cu(I)-
catalyzed azide-alkyne cycloaddition (CuAAC) for fluorescence visualization or 
quantitative proteomics methods such as stable isotope labeling by amino acids in cell 
culture (SILAC) (Figure 4). Specifically, SILAC enables the evaluation of 
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signal/background ratios to identify fatty-acylated proteins with high confidence as well as 
the comparison of the protein acylation level (Peng et al., 2016). 
 
Figure 4. Detection of protein fatty-acylation using chemical reporters. Alkyne-
bearing chemical reporters are fed to the cells. After uptake and metabolic incorporated 
into proteins, cells are lysed and subjected to subsequent CuAAC ligation with either 
fluorophore for imaging or biotin for proteomics study. 
 
One of the advantages of using chemical reporters is the ability to apply to versatile 
lipid modifications on proteins, including S-fatty-acylation, N-myristoylation and S-
prenylation. They also offer more sensitive and immediate detection compared to 
radioactive methods. After probes have been incorporated into proteins, samples can be 
processed and reacted through bioorthogonal chemistries with fluorophore conjugates for 
visualization or biotin conjugates for enrichment. Furthermore, dynamic S-fatty-acylation 
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can be readily monitored using pulse-chase analysis with fatty acid reporters (az-16 or alk-
16) (Martin et al., 2012; Zhang et al., 2010). 
Table 2. List of chemical reporters for fatty-acylation. 
Acylation Reporter chemical 
structure 
References 
S-palmitoylation 
, Alk-16 or ODYA 
(Charron et al., 2009b; 
Hannoush and Arenas-
Ramirez, 2009) 
 
, HDYOA 
(Yount et al., 2011a) 
 
, Alk-14 
(Charron et al., 2009a; 
Hannoush and Arenas-
Ramirez, 2009) 
 
, Az-15 
(Charron et al., 2009a; 
Hang et al., 2007) 
 
, Az-14-CoA 
(Kostiuk et al., 2008) 
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Table 2. List of chemical reporters for fatty-acylation (continued). 
Acylation Reporter chemical 
structure 
References 
N-myristoylation 
, Alk-11 
(Hannoush and Arenas-
Ramirez, 2009) 
 
, Alk-12 
(Charron et al., 2009a; 
Hannoush and Arenas-
Ramirez, 2009; Heal et al., 
2008a) 
 
, Alk-12-CoA 
(Heal et al., 2008a) 
 
, Az-11 
(Heal et al., 2008a) 
 
, Az-12 
(Charron et al., 2009a; 
Hang et al., 2007; Martin et 
al., 2008) 
 
, Az-11-CoA 
(Heal et al., 2008a, 2008b) 
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1.2.3 Acyl-biotin exchange method for S-fatty-acylation detection and enrichment 
Unlike N-/O- acylation, thioester linkage is sensitive to nucleophilic reagents that can be 
exploited for detection and enrichment. Drisdel and Green developed acyl-biotin exchange 
(ABE) chemistry to take advantage of the free thiol that is liberated by hydroxylamine 
(NH2OH) to be labeled with a Cys-reactive reagent (Drisdel and Green, 2004). In the first 
step, cell extracts are treated with N-ethylmaleimide (NEM) to block free Cys residues. 
One-half of the sample is then treated with NH2OH to remove fatty acids from Cys residues, 
whereas the other half is the control sample. Reactive biotin reagents like HPDP-Biotin 
(N-[6-(Biotinamido)hexyl]-3 ́-(2 ́-pyridyldithio)propionamide) can then be used to label 
newly liberated Cys residues. Biotinylated proteins are then captured on a streptavidin 
column and eluted. Eluted proteins can be either visualized by SDS-PAGE or analyzed by 
proteomics (Figure 5A). A S-palmitoylated protein should be present in the NH2OH-treated 
sample, but absent from the control sample. 
Compared to the chemical reporters method, ABE does not require metabolic 
labeling so it can be used to analyze S-acylated proteins in native cells, tissues, and 
biofluids (Zhou et al., 2014). ABE has been used to analyze global protein palmitoylation 
in the yeast, which identified thirty five new S-palmitoyl proteins including many SNARE 
proteins and amino acids permeases as well as other participants in cellular signaling and 
membrane trafficking pathway (Roth et al., 2006). While ABE has the potential to capture 
the full S-acylproteome, chemical reporters only capture proteins that are dynamic and 
turnover during the metabolic labeling window, which indicates that metabolic labeling 
method is potentially biased towards the enrichment of proteins with fast S-fatty-acylation 
turnover.  
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Figure 5. Methods for analysis of fatty-acylated proteins. A) Acyl-biotin exchange 
(ABE). B) Acyl-RAC. C) Acyl-PEG exchange (APE). 
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1.2.4 Acyl-RAC method for S-fatty-acylation detection and enrichment 
ABE is readily adapted to immunoblotting techniques and is also adaptable to mass 
spectrometric-based identification of individual S-acylated proteins (Kang et al., 2008; 
Roth et al., 2006; Yang et al., 2010a). However, the detection of biotinylated proteins 
requires repeated protein precipitations, SDS neutralization, and streptavidin pull-down. 
An alternative to ABE that uses the detection of S-acylated proteins via resin-assisted 
capture (acyl-RAC) instead of biotinylation was proposed (Forrester et al., 2009, 2011; 
Ren et al., 2013). Specifically, acyl-RAC method was initially described as a methodology 
to identify S-nitrosylation sites in proteins and later developed to apply on S-fatty-acylation. 
Coupled with mass-spectrometry proteomics, acyl-RAC can be also used to enrich and 
identify S-acylproteome (Figure 5B). Compared with ABE, which involves multiple steps 
of precipitation and resolubilization of samples, acyl-RAC method use thiolpropyl 
sepharose to eliminate the biotin enrichment steps so the purification scheme is relatively 
simplified (Zhou et al., 2014). This method can also be generalized to study other cysteine-
based reversible modifications, including disulfide formation, S-nitrosylation (SNO), and 
S-glutathionylation (SSG), by varying reducing reagents such as ascorbate, glutaredoxin, 
DTT, or NH2OH, respectively (Guo et al., 2014). 
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 Acyl-RAC has been used to detect S-fatty-acylation of overexpressed and 
endogenous H-Ras in mammalian cell system in an NH2OH-dependent manner. Double 
mutants C181,184S, which are not S-acylated, were not detected, which further validate 
the specificity of acyl-RAC method. Coupled with mass spectrometry and isobaric labeling 
method, acyl-RAC was able to identify new S-acylated substrates, such as the β-subunit of 
the protein translocating system (Sec61b), ribosomal protein S11 (Rps11), and microsomal 
glutathione-S-transferase 3 (MGST3) (Forrester et al., 2011). 
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1.2.5 Acyl-PEG exchange method for S-fatty-acylation detection and enrichment 
To evaluate endogenous levels of S-fatty-acylation, our laboratory developed a mass-shift 
labeling method that exploits the NH2OH-sensitivity of thioesters and selective reactivity 
of Cys residues for site-specific alkylation with maleimide-functionalized polyethylene 
glycol reagents, termed acyl-PEG exchange (APE) (Figure 5C). APE induces a mass-shift 
on S-acylated proteins that can be readily monitored by western blot analysis of target 
proteins and circumvents the need for metabolic labeling or affinity enrichment of proteins. 
More importantly, acyl-PEG exchange method reveals the ratio of unmodified versus S-
fatty-acylated proteins or multiple sites of S-fatty-acylation, which is critical for 
understanding how quantitative differences in S-fatty-acylation level control protein 
function and associated cellular phenotypes. APE provides a sensitive and readily 
accessible method of evaluating endogenous S-fatty acylation levels and should facilitate 
the quantitative analysis of this dynamic lipid modification in diverse cell types and tissues 
(Percher et al., 2016). 
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1.2.6 Comparison of different methods for protein S-fatty-acylation detection and 
enrichment 
In general, two major methods exist for S-fatty acylation: first is metabolic chemical 
reporter labeling method, in which synthetic fatty acids analogs with bioorthogonal handles 
are incorporated into proteins on cysteine residues; the second is to use reversible 
modifications of cysteine thiols to label S-acylated residues. The two methods complement 
each other and are best used together to avoid some of the biases. 
Firstly, ABE, acyl-RAC, or APE does not require metabolic labeling so it can be 
used to analyze S-acylated proteins in native cells, tissues, and biofluids. In comparison, 
chemical reporters metabolic labeling requires feeding and uptake of chemical reporters 
beforehand. Secondly, ABE, acyl-RAC, APE have the potential to capture the full S-
acylproteome, while chemical reporters theoretically only capture proteins that become S-
acylated during the metabolic labeling window, which tends to label proteins with fast 
turnover (Zhou et al., 2014). However, metabolic labeling has considerable advances in the 
past decade. Development of bioorthogonal reactions enables versatile chemical reporters 
for various kinds of modifications. The ability to pulse reporters at a specific time into cell 
culture, tissue or animals provides information about the dynamics of the modification 
(Martin et al., 2012; Zhang et al., 2010). 
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1.3 Discovery of new fatty-acylated proteins from chemical proteomics 
1.3.1 Summary of proteomics studying using chemical reporter and ABE method 
It has been challenging to study protein fatty acylation due to lack of specific antibody and 
limited methods. However, some of the methods developed as mentioned above enabled 
specific enrichment and large-scale analysis using mass spectrometry. Metabolic chemical 
reporters introduce alkyne or azide tag into fatty-acylated proteins, which allows 
bioorthogonal reactions with affinity tags (e.g., biotin) for selective enrichment and large-
scale proteomic identification (Peng et al., 2016). This chemical reporter strategy has been 
widely employed for the global analysis of N-myristoylated and S-palmitoylated proteins, 
and can in principle be used for other fatty-acylated proteins. Alternatively, NH2OH-
mediated ABE or acyl-RAC methods utilize HPDP-biotin or thiolpropyl sepharose to 
capture and enrich S-acylated proteins for mass spectrometry analysis (Thinon and Hang, 
2015).  
 Those selective methods have allowed the large-scale analysis of fatty-acylated 
proteins in different cell types and animals and more than 300 fatty-acylated proteins have 
been identified to date, suggesting broader roles of fatty-acylation in regulating eukaryotic 
biology than previously appreciated (Thinon and Hang, 2015). To label N-myristoylation 
proteins, alk-12 is preferred reporters because comparative analysis of different analogs 
like alk-11, alk-12, az-11 and az-12 showed that alk-12 in combination with azide-tagged 
fluorophores gives minimal background labeling. Alk-12 also labels N-myristoylated 
proteins better than other longer-chain fatty acid reporters (Charron et al., 2009a; Wilson 
et al., 2011). However, it becomes complicated when chemical reporters enter the cell and 
are metabolized to other alkyne containing molecules. It should be also noted that some of 
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the fatty-acylation process is highly promiscuous which tolerates chemical reporters 
labeling non-specifically (Jiang et al., 2013). To mediate the artifact effects of false positive 
candidates, several strategies have been used. First one is to use NMT inhibitors to test 
whether the enriched proteins are dependent on NMT inhibitors or not to reliably identify 
NMT substrates. Wright et al. quantitatively profiled N-myristoylation in malaria parasites 
using chemical reporters, NMT inhibitors and validated NMT as a potential drug target 
(Wright et al., 2014). Further analysis of global co-translationally and post- translationally 
N-myristoylated proteome in human cells has identified over 100 NMT substrates, 
including 40 proteins that are post-translationally N-myristoylated, following caspase 
cleavage, during apoptosis (Thinon et al., 2014). Further application of this strategy in 
parasites such as Leishmania donovani, revealed 30 high confidence NMT substrates with 
more than half uncharacterized previously (Wright et al., 2015). However, due to the 
toxicity of NMT inhibitors, not all the systems will work with this strategy. Another way 
to differentiate N-myristoylation from other forms of fatty acylation is to use the criteria of 
possession of N-terminal glycine. Studies on global profiling of host N-myristoylated 
proteins in cells infected by herpes simplex virus (HSV) or human immunodeficiency virus 
1 (HIV-1) revealed protein fatty-acylation during infection (Colquhoun et al., 2015; Serwa 
et al., 2015). Another N-myristoylation study in the context of bacterial infection was 
focused on Gram-negative bacteria Shigella effector protein IpaJ (Burnaevskiy et al., 2015). 
IpaJ specifically demyristoylates Golgi-associated ARF/ARL family GTPases during 
Shigella infection which suggests important concerted mechanism of proteolytic 
demyristoylation. 
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 Proteomics studies on S-fatty-acylation using ABE, acyl-RAC or chemical 
reporters methods have made a tremendous contribution to our understanding of this 
reversible modification (Thinon and Hang, 2015). Indeed, there were over 20 proteomics 
profiling studies on identification of dynamic S-acylated proteins and substrates of DHHC 
or deacylation enzyme (Table 3). The palmitoyl acyltransferases (PATs) encoded by 
ZDHHC genes (5 in fission yeast, 7 in budding yeast, 23 in human, 24 in mouse and 
Arabidopsis) are responsible for catalyzing the formation of thioester bond on cysteine 
residue with fatty acyl-CoA. Since there are redundant genes for this enzymatic activity, 
one important question that remains to be solved is the function and specificity of each 
DHHC-PAT enzyme. In cells, DHHC-PATs are localized to different compartments such 
as the endoplasmic reticulum, the Golgi apparatus, plasma membrane, and endocytic 
vesicles. The first global study in Saccharomyces cerevisiae by Roth et al. compared the 
differences in the S-fatty-acylation levels of 30 abundant S-acylated proteins before and 
after the deletion of one to six DHHC-PATs (Roth et al., 2006). They were able to identify 
35 new S-palmitoylated proteins and reveal the diverse enzymatic specificities of 
individual DHHC-PATs. A global analysis of rat neural S-palmitoylome using the ABE 
method identified most of the known neural palmitoyl proteins and more than 200 new S-
palmitoylated protein candidates with diverse functions, including neurotransmitter 
receptors, transporters, scaffolding proteins, as well as vesicular trafficking proteins (Kang 
et al., 2008). 
 S-palmitoylome study using chemical reporters in dendritic cells (DC2.4) identified 
more than 150 candidate S-palmitoylated proteins and revealed that S-palmitoylation is 
crucial for the antiviral activity of IFITM3 as well as the activity of Toll-like receptor 2 
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(TLR2), both of which are crucial immune-related proteins, highlighting the importance of 
S-fatty-acylation in control of immune response (Chesarino et al., 2014a; Yount et al., 
2010). Quantitative proteomics with ABE and Stable Isotope Labeling of Mammals 
(SILAM) has also enabled protein S-palmitoylation profiling in more complex biological 
samples (Wan et al., 2013) (Table 3). 
 The advances that have been made on understanding of protein fatty-acylation and 
the scale of proteome that is regulated by these modifications enable us to design new drug 
targets deepen our understanding of the biological function. Though we should also 
recognize that there are limitations of current methods. The first one is to understand the 
native S-fatty-acylation of endogenous proteins. Both ABE or metabolic labeling methods 
ignore or presume the fatty acid to be palmitate. However, other long chain fatty acids like 
palmitoleate, stearate, oleate, arachidonate, and eicosapentaenoic acid can also modify 
proteins on cysteine residues. Mass spectrometry analysis of intact S-acylated peptides can 
provide direct evidence of the fatty acids composition. 
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Table 3. Summary of literature on proteomics study of fatty-acylated proteins 
Species Method References 
Saccharomyces 
cerevisiae 
ABE (Roth et al., 2006),  
Embryonic rat 
neurons 
ABE (Kang et al., 2008) 
Jurkat T cells Chemical reporter (Martin and Cravatt, 2009), (Wilson et al., 
2011) 
Macrophage ABE (Merrick et al., 2011) 
Human B cells ABE (Ivaldi et al., 2012) 
Plasmodium 
falciparum 
ABE/Chemical 
reporter 
(Jones et al., 2012) 
Neuronal stem cell Chemical reporter (Li et al., 2012)a 
Endothelial cell ABE (Marin et al., 2012)a, 
Mouse brain ABE (Wan et al., 2013) 
. 
  
28 
 
1.3.2 Discovery of IFITMs S-fatty-acylation 
Proteomic analysis of fatty-acylated proteins in murine dendritic cell line (DC2.4) using a 
palmitic acid reporter (alk-16) and bioorthogonal ligation methods by our laboratory 
recovered known S-palmitoylated proteins (i.e. NRas, CANX) as well as many new 
candidate S-fatty-acylation proteins such as IFITMs that are directly involved in host 
immunity to pathogens (Yount et al., 2010) (Figure 6). The S-fatty-acylation on IFITM3 is 
NH2OH-sensitive, and loss of S-fatty-acylation by mutagenesis of all three Cys residues 
inactivates IFITM3. The first two Cys residues are at the edge of the first helical domain 
while the third Cys is near the second helical domain. The two helical domains are 
predicted to be transmembrane, but the exact topology of IFITM3 remained to be 
determined. 
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Figure 6. Visualization and identification of S-palmitoylated proteins in dendritic 
cells. A) Metabolic labeling of cells with alk-16 palmitate reporter and subsequent CuAAC 
ligation with bioorthogonal detection tags for imaging or proteomics. B) and C) DC2.4 
cells were incubated for two hours with 50 mM alk-16 or DMSO as a control. In B), cell 
lysates were reacted with az-rho by CuAAC, and proteins were separated by SDS-PAGE 
for visualization by fluorescence gel scanning. Coomassie blue staining demonstrates equal 
loading. In C), cell lysates were reacted with az-diazo-biotin by CuAAC for the enrichment 
of alk-16–labeled proteins with streptavidin beads and identification by mass spectrometry. 
For each identified protein, the ratio of peptide spectral counts from the alk-16 and DMSO 
samples was plotted. Several known palmitoylated proteins are shown in black. IFITM3, 
the highest-ranked candidate S-palmitoylated protein, is shown in red. Figure is taken from 
(Yount et al., 2010).  
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Chapter Two: Characterization of IFITM3 S-palmitoylation 
2.1 Summary 
Interferon-induced transmembrane protein (IFITM) family proteins are unique interferon-
induced proteins that restrict the infection of multiple pathogenic viruses. Our laboratory 
discovered that S-palmitoylation and ubiquitination of IFITM3 are critical for its antiviral 
activity. While overexpression of wild-type mouse or human IFITM3 in mammalian cell 
lines significantly reduced influenza A virus (IAV) infection, overexpression of the S-
palmitoylation deficient (Palm∆) IFITM3 mutant had no antiviral activity. Notably, 
mutation of Cys72 to Ala (C72A) in both mouse and human IFITM3 constructs increased 
the infection level, and additional mutation of Cys71 to Ala (C71A) further reduced the 
antiviral effect to the level similar to that of Palm∆ IFITM3. Bioinformatics studies on the 
IFITM family of proteins across 27 vertebrates reveals that CD225 domain and all three 
cysteines are highly conserved, Especially C72 is more conserved than C71 and C105. To 
quantify the endogenous levels of IFITM3 palmitoylation, we developed a mass-shift assay 
based on hydroxylamine-sensitivity of thioesters and selective maleimide-modification of 
Cys residues, termed the acyl-PEG exchange (APE). Using metabolic chemical reporter 
labeling and APE methods, we demonstrated that IFITM3 is S-fatty-acylated on three Cys 
residues, but specific sites and fatty acylation levels are vital for its antiviral activity. 
We observed lower protein expression levels of human IFITM3 C72A mutant in 
HeLa and lung epithelial cells, suggesting S-palmitoylation might regulate the stability of 
IFITM3. To understand the precise mechanism(s) by which IFITMs prevent virus entry, 
we generated hIFITM1, 2, 3 deletion cell lines utilizing CRISPR/Cas9 technology. We then 
performed a cycloheximide (CHX) chase assay in HeLa IFITM2/3 knockout (KO) cell 
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lines with overexpressed IFITM3 WT and cysteine mutants with or without 
proteasome/lysosome/p97 inhibitor to identify which pathway is responsible for IFITM3 
degradation. 
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2.2 Introduction 
2.2.1 Early findings on IFN-induced effectors 
Interferons (IFN) are a group of cytokines made and released from host cells to inhibit 
pathogen infection by inducing expression of more than 300 IFN-stimulated genes (ISGs) 
(MacMicking, 2012; Sadler and Williams, 2008). Type I IFNs activate host pathways to 
inhibit the replication of most viruses. Humans deficient in components of type I IFN 
signaling are particularly vulnerable to viral disease. This innate system of defense limits 
viral infections through the induction of ISGs but the antiviral mechanisms for many of 
these genes remain to be determined.  
 As early as the 1950s, researchers observed that under certain conditions virus-
infected cells are resistant to a second virus infection. It also had been demonstrated that 
inactivated IAVs can interfere with live IAVs, even though the mechanism or substance 
that mediates this process was not known (Henle, 1950). In 1957, the term “interferon” was 
coined by Isaacs & Lindenmann to describe the substance that interferes with IAV (Isaacs 
and Lindenmann, 1957; Isaacs et al., 1957). By the 1980s, it was shown that IFN is a small 
protein produced and secreted by cells (Lengyel, 1982). It had been nearly two decades 
since the initial description of IFN before methods were developed to allow sufficient 
purification and more rigorous characterization of IFN properties (Pestka, 2007). 
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2.2.2 Discovery of antiviral activity of IFITMs towards different viruses 
IFITM family was recently shown to mediate a significant portion of the IFN-associated 
response. IFITMs appear to be conserved in vertebrates with 5 homologs in humans 
(IFITM1, 2, 3, 5 and 10) and 7 in mice (Ifitm1, 2, 3, 5, 6, 7 and 10). Murine embryonic 
fibroblasts (MEFs) deficient in Ifitm3 were more readily infected with influenza virus than 
control cells, before and particularly after treatment with IFNα when compared to wild-
type MEFs. In addition, overexpression studies have shown that IFITM3/Ifitm3 is the most 
active isoform and also provides antiviral activity against many other pathogenic viruses 
including, hepatitis C virus (HCV), dengue virus, West Nile virus, vesicular stomatitis 
virus (VSV), human immunodeficiency virus (HIV), and SARS virus (Bailey et al., 2012; 
Brass et al., 2009; Everitt et al., 2012; Schoggins et al., 2011; Yount et al., 2010). (Table 
4).  
Table 4. List of viruses suppressed by IFITMs.  Taken from (Perreira et al., 2013) 
 
  
34 
 
2.2.3 IFITM3 posttranslational modifications, localization and membrane topology 
IFITMs are relatively small proteins (133 - 137 amino acids) that were originally predicted 
to be dual-pass transmembrane proteins based on two hydrophobic domains (Brass et al., 
2009). Subsequent biochemical studies from our laboratory revealed that mIFITM3 is also 
ubiquitinated on four conserved lysines (K24, K83, K88, K104), mostly on K24, which 
regulates IFITM3 stability, antiviral activity and localization (Yount et al., 2012) (Table 5). 
Tyr20 was later reported to be phosphorylated (Chesarino et al., 2014b; Jia et al., 2012). 
The identification of K24 ubiquitination on IFITM3 raised the possibility that the predicted 
dual-pass transmembrane topology was incorrect since the enzymes responsible for 
ubiquitin conjugation are localized in the mammalian cytosol (Yount et al., 2012). 
Subsequent N-linked glycosylation mapping studies and protein lipidation engineering (N-
myristoylation and C-prenylation) studies, in conjunction with immunofluorescence 
analysis and antiviral activity assays from our laboratory suggest that mIFITM3 may be an 
intramembrane protein where both the N- and C-termini of mIFITM3 have access to the 
cytoplasm (Yount et al., 2012). In addition to S-fatty-acylation and ubiquitination, 
phosphorylation of Tyr20 has also been reported to regulate IFITM3 endocytosis from the 
plasma membrane (Chesarino et al., 2014a; Jia et al., 2014). More recent epitope-mapping 
studies have also confirmed the cytoplasmic orientation of IFITM3 N-terminus and suggest 
that the C-terminus may either be luminal or extracellular (Bailey et al., 2013; Weston et 
al., 2014). These studies collectively suggest that the IFITM proteins may adopt an 
intramembrane or type II membrane protein topology, or both, in mammalian cells (Figure 
7). 
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Figure 7. Topology model of IFITM3. From left to right, predicted dual-pass 
transmembrane topology, intramembrane topology and type II membrane topology models. 
 
Table 5. Summary of post-translational modifications on IFITM3. 
Residue PTM Function* 
Y20 Phosphorylation Localization 
K24 Ubiquitination  Stability, anti-viral activity 
C71 S-fatty-acylation Stability, localization, anti-viral activity 
C72 S-fatty-acylation Stability, localization, anti-viral activity 
K83 Ubiquitination  Stability, anti-viral activity 
K88 Ubiquitination  Stability, anti-viral activity 
K104 Ubiquitination  Stability, anti-viral activity 
C105 S-fatty-acylation Stability, localization, anti-viral activity 
 The exact function of each PTM is still not very clear 
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Our laboratory has further demonstrated the antiviral activity of Ifitm3 is dependent 
on S-palmitoylation of all three membrane-proximal Cys residues as well as ubiquitination 
of conserved Lys residues that regulate IFITM3 protein turnover and localization to 
endolysosomes. However, the precise mechanisms of how S-fatty-acylation of IFITM3 
controls its antiviral activity, and protein stability are still unclear. Sequence alignment of 
IFITM family from human, mouse, and chicken revealed highly conserved cysteine 
residues across all species (Figure 8), which highlights the importance of S-fatty-acylation 
during the evolution of IFITM family. To follow up on our previous study of mouse 
IFITM3, we focused on human IFITM3. 
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Figure 8. Sequence alignment and predicted topology of IFITM proteins. Human, 
mouse, and chicken IFITM protein family sequences are aligned. Red residues indicate that 
at least nine of twelve IFITM proteins are conserved. The site of palmitoylation is 
highlighted in orange. Green and blue highlighting indicate species-specific signature 
residues of humans and mice, respectively, possibly suggesting interaction with a cofactor 
that similarly diverged in each species. Blue stars indicate conserved cysteines position. B) 
Membrane topology models of IFITM3. 
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2.3 Results 
2.3.1 S-fatty-acylation of human IFITMs 
Our lab previously discovered that S-fatty-acylation of membrane-proximal Cys on 
murine IFITM3 enhances its clustering and is crucial for its inhibitory activity toward 
influenza virus infection (Yount et al., 2010). However S-fatty-acylation does not appear 
to influence the protein levels of overexpressed murine IFITM3 in human HeLa cells, as 
judged by western blot, immunofluorescence, and flow cytometry analysis (Yount et al., 
2010), (Figure 9). For our studies of human IFITM3, expression of Cys-to-Ala mutants in 
A549 revealed that all three Cys residues are S-acylated, indicating a conserved pattern of 
S-fatty-acylation (Figure 10). Alkynyl palmitate reporter alk-16 was used to detect IFITM3 
S-fatty-acylation as shown in Figure 9 and Figure 10. Specifically, 50 µM Alk-16 was 
pulsed for one hour after transfection with respective IFITM3 constructs. Cells were then 
harvested and immunoprecipitated using α-HA antibody conjugated resin. On-bead click 
chemistry was then performed and the in-gel fluorescence level was measured using 
Typhoon biomolecule imager. Interesting, the human IFITM3 C72A mutant affects not 
only its S-palmitoylation but also protein expression levels (Figure 10). C71A has lower 
expression level compared to the wild-type and but still higher than C72A. We then 
performed a similar analysis on human IFITM1 and IFITM2 (Figure 11). All three IFITMs 
orthologues were S-acylated on the conserved Cys. Interestingly, IFITM2 and IFITM3 
showed doublet bands in in-gel fluorescence results while IFITM1 only showed a single 
band. Sequence alignment showed IFITM1 has a shorter N-terminal domain, but all three 
proteins have conserved CD225 domain including three Cys at similar positions near the 
helical domain (Figure 9). Mutagenesis analysis of single Cys to Ala showed that the 
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middle Cys expressed consistently lower level proteins, which suggests a conserved 
function of this key Cys residue on IFITM protein stability (Figure 11)  
 
 
Figure 9. S-fatty-acylation of murine IFITM3 and Cys mutants. NIH3T3 cells 
transfected with HA-mIFITM3 constructs were metabolically labeled for two hours with 
50 µM alk-16. Cell lysates prepared with 1% Brij 97 were subjected to 
immunoprecipitation with anti-HA agarose beads, reacted with az-rho by CuAAC, 
separated by SDS-PAGE and visualized by fluorescence gel scanning. Comparable protein 
loading was confirmed by anti-HA western blotting (Data from Jacob Yount). 
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Figure 10. S-fatty-acylation of human IFITM3 and Cys mutants in A549 cells. Human 
IFITM3 plasmid was subcloned into N-HA vector to create pCMV-HA-hIFITM3 plasmid. 
Single, double and triple (PalmΔ) mutations were made using QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent). A549 cells were plated in growth medium without 
antibiotics the day before the experiment and then trasfected with indicated plasmids using 
Lipofectin® 2000 (Invitrogen). After 18 hours of incubation, cells were labeled with alk-
16 reporter for one hour. Cells were then lysed in 1% Brij97 buffer with EDTA-free 
protease inhibitors. After centrifugation to get rid of cell debris, the supernatant was 
immunoprecipitated with EZviewTM anti-HA agarose (Sigma-Aldrich). After washing with 
RIPA buffer for three times, on beads click chemistry was then performed and incubated 
for one hour at room temperature. Beads were washed again with RIPA buffer for three 
times before adding loading buffer and subject to SDS-PAGE. Two identical gels are 
subjected to western blot analysis and in-gel fluorescence respectively. 
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Figure 11. S-fatty-acylation of human IFITMs in HEK293T cells. In-gel fluorescence 
detection of alk-16 labeled proteins and α-HA western blot of the same gel were performed 
to show protein expression and S-fatty-acylation. A) Wild-type pCMV-HA-IFITM1, 
pCMV-HA-IFITM2, and pCMV-HA-IFITM3 were transfected into HEK293T cells before 
labeling with Alk-16. B) Single cysteine mutations IFITM1 C50A, C51A, C84A, IFITM2 
C70A, C71A, C104A and IFITM3 C71A, C72A, C105A, were labeled with alk-16 and S-
palmitoylation was measured using in-gel fluorescence. 
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2.3.2 Characterization of endogenous and site-specific S-fatty-acylation levels of 
IFITM3 in mammalian cells 
Our site-directed mutagenesis studies and alk-16 labeling revealed that all three Cys 
residues can be S-acylated. However, mutation of Cys to Ala may affect properties other 
than S-fatty-acylation and does not reveal the endogenous levels of IFITM3 S-fatty-
acylation. To address these challenges, our laboratory has developed a mass-shift detection 
method based on NH2OH-sensitivity of thioesters and selective maleimide-modification of 
Cys, termed acyl-PEG exchange (APE). The protocol of APE is discussed in Chapter 1.2. 
We first tested APE for detection of S-fatty-acylation of endogenous IFITM3 from 
NIH3T3 and Raw264.7 cell lines (Figure 12), which revealed three slower migrating 
PEGylated polypeptides in SDS-PAGE that likely correspond to the mono-, di-, and tri-S-
fatty-acylated isoforms of mIFITM3. Unmodified IFIMT3 is far less abundant than the 
PEGylated proteins, which indicated that most of the endogenously expressed mIFITM3 
in IFN-stimulated cells are S-acylated on one or more Cys residues. The analysis of 
endogenous human IFITM3 in A549 cells also revealed similar results to mouse IFITM3 
(Figure 13). Endogenous Calnexin 1 (CANX) that is dually S-palmitoylated was used as a 
control for protein loading and APE (Lakkaraju et al., 2012). 
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Figure 12. Endogenous mIFITM3 S-palmitoylation assessed by APE. NIH3T3 or 
RAW264.7 cells were activated with 500 ng /mL LPS, 100 U/mL IFN-γ for 16 hours, 
subjected to APE, separated by SDS-PAGE and analyzed by western blot (Data from 
Percher et al., 2016) 
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Figure 13. Endogenous human IFITM3 S-fatty-acylation in A549 cells. A549 cells 
were activated with 500 ng/mL LPS, 100 μg/mL IFN-γ or IFN-α for 16 hours, subjected to 
APE, separated by SDS-PAGE and analyzed by western blot. (Data from Percher et al., 
2016) 
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To evaluate the contribution of individual Cys residues on IFITM3 S-fatty acylation 
levels, we generated single and double Cys mutants and analyzed their levels of S-fatty 
acylation by APE and metabolic labeling methods. APE analysis of the wild-type and the 
individual Cys to Ala HA-mIFITM3 mutants transfected into unstimulated murine NIH3T3 
fibroblasts showed that mutation of Cys71 and 105 to Ala eliminated the tri-S-acylated 
fraction and decreased the levels of the mono- and di-S-acylated mIFITM3. In contrast, the 
C72A mutant or multiple Cys mutants containing C72A abrogated the tri- and di-S-
acylated IFITM3 and even lost the mono-S-acylated fraction for C72,105A mutant (Figure 
14). A similar trend was also observed for human IFIMT3 APE experiment (Figure 15). 
The comparison of APE and alk-16 labeling suggests that while the C72A IFITM3 mutant 
is still significantly mono-S-fatty-acylated, the majority of fatty acid metabolic labeling is 
abrogated (Figure 10 and Figure 15). These data suggested that quantitative differences of 
dynamic S-fatty-acylation may contribute to the function of IFITM3. 
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Figure 14. APE analysis of overexpressed mIFITM3 and Cys mutants. NIH3T3 cells 
transfected with WT HA-mIFITM3 or Cys to Ala mutant constructs were subjected to APE, 
separated by SDS-PAGE and analyzed by western blot. Analysis of whole cell lysate 
(WCL) indicates levels of protein expression without APE. 
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Figure 15. APE of overexpressed human IFITM3 and mutants. HEK293T cells 
transfected with WT and mutant HA-IFITM3 constructs were analyzed using APE protocol. 
For the wild-type sample, with or without hydroxylamine (HA) controls were both used. 
Star indicated the mono-, di-, and tri-S-palmitoylated species. 
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2.3.3 Anti-influenza virus activity of IFITM3 S-palmitoylation mutants 
We next evaluated the antiviral activity of IFITM3 Cys mutants using flow cytometry 
staining with influenza virus NP-specific antibodies, as previously described by our 
laboratory (Yount et al., 2010, 2012). The analysis of HA-IFITM3-PalmΔ mutant activity 
against H1N1 influenza virus (type A, PR8 strain) infection confirmed this S-
palmitoylation deficient has decreased antiviral activity. Interestingly, both mouse and 
human IFITM3 C72A had significantly less activity compared to C71A (Figure 16). 
Moreover, C71, 72A double mutant showed loss of activity similar to the level of PalmΔ, 
which suggested that C71 and/or C72 are necessary for the activity of IFITM3. On the 
other hand, C71A hardly affected antiviral activity, which suggests a crucial role of Cys72 
S-fatty-acylation for the full antiviral activity of IFITM3. Note that single C105A mutant 
also had decreased activity to a very low level especially for mouse IFITM3, however 
IFITM3 double mutants C71,72A with only one Cys105 was inactive (Figure 16) 
indicating Cys105 is essential but not sufficient for the activity of IFITM3. 
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Figure 16. Antiviral activity of WT and IFITM3 Cys mutants. A) NIH3T3 fibroblasts 
were transfected with vector or HΑ-mIFITM3 plasmids, then infected with influenza A 
virus (PR8 strain) for six hours and analyzed by flow cytometry using α-HA antibody to 
identify HA-mIFITM3 expressing cells and α-NP to analyze the number of IAV-infected 
cells. B) HEK293T cells were transfected overnight with indicated plasmids before a 6-h 
infection with influenza virus at a multiplicity of infection of 2.5 and analyzed by flow 
cytometry. Cells expressing IFITM3 constructs were analyzed for the percentage of cells 
that were infected using influenza specific anti-NP antibodies. 
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2.3.4 Immunofluorescence analysis of IFITM3 Cys mutants in mammalian cells. 
To understand the mechanism of action of IFITM3 S-fatty-acylation, we investigated the 
influence of S-palmitoylation on IFITM3 expression and distribution in cells. 
Immunofluorescence analysis revealed that mIFITM3 is distributed into punctate clusters. 
Loss of S-palmitoylation led to decreased co-localization with lysosome marker LAMP1 
(Figure 17). However, the quantitative analysis did not show enough statistical difference 
between IFITM3 WT and C72A mutant. Similarly, we transfected human IFITM3 WT and 
Cys mutants in HeLa cells and analyzed their colocalization with GFP-LAMP1 (data not 
shown). Even though we initially observed altered colocalization of hIFITM3 C72A and 
PalmD with GFP-LAMP1, these differences were not still not statistically significant. 
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Figure 17. Imaging of HA-mIFITM3 in NIH3T3 fibroblasts. NIH3T3 cells grown on 
coverslips in 12-well plates were transfected with one μg pCMV-HA-mIFITM3 WT, C71A, 
C72A, C105A and PalmΔ and stained with anti-HA (red) and DAPI (blue). Scale bars 
represent five μm. Cells were also co-transfected with lysosomal markers, LAMP1-GFP 
(green). 
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2.3.5 Protein turnover of human IFITM3 and Cys mutants 
To understand how Cys mutation affects IFITM3 protein stability, we investigated whether 
S-fatty-acylation affected IFITM protein stability in cycloheximide (CHX) chase 
experiments. For these experiments, CHX is added to cells, and the decay in the steady-
state level of a target protein is monitored by immunoblotting. Normalized protein 
expression data is then fitted into protein decay model to calculate rate constant and half-
life. I then compared the differences between wild-type IFITM3 and Cys mutants. To avoid 
the complication of endogenous IFITM3, our lab has generated IFITM3 knockout HeLa 
and A549 cell lines, using CRISPR-Cas9 gene targeting technology (Ruina He). 
 For the IFITM3 turnover experiments, IFITM2/3 -/- knockout HeLa cells were used 
to avoid heterotypic interaction with endogenous IFITMs. Transient expression of IFITM3 
WT, C72A, and PalmΔ plasmids was performed in IFITM2/3 -/- knockout cells, which 
were then treated with inhibitors at different concentrations for 12 hours before analysis 
using immunoblotting (Figure 18). Quantification of normalized proteins level showed that 
proteasome, lysosome, and p97 inhibitors can increase protein expression. Interestingly, 
the p97 inhibitor ML240-treated sample showed the highest expression level and stability. 
ML240 is a selective, ATP-competitive inhibitor of p97/VCP. VCP has been shown to 
mediated turnover of ubiquitin-labeled proteins for recycling or degradation by the 
proteasome but also has functional relevance to lysosomal degradation for similar proteins 
to IFITM3 such as caveolin (Meyer et al., 2012). 
After I identified working concentration for different inhibitors at a single time 
point, I profiled dynamic changes of protein expression at various time points (Figure 19). 
IFITM2/3 -/- HeLa cells were transfected with hIFITM3 WT, C72A, and PalmΔ constructs. 
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After transfection for 16 hours, 25 μg/ml CHX was added to the cell culture to inhibit 
protein synthesis. Cells were harvested at designated time points and snap-freezed for 
further analysis. After lysis with 4% SDS buffer, protein expression level in homeostasis 
was detected using α-HA and α-GAPDH immunoblotting. Triplicates of the same 
experiment were performed and the normalized IFITM3 expression level was plotted. I 
then fit the data using one-phase decay from Graphpad Prism (Figure 20). Rate constants 
of IFITM3 WT, C72A, and PalmΔ were calculated (Table 6). 
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Figure 18. Protein turnover of IFITM3 WT, C72A, and Palm∆ in HeLa IFITM2/3 -/- 
cell line. HeLa IFITM2/3 -/- cells were plated into 12-well plates before transfection. 
pCMV-HA-IFITM3 WT, C72A, and PalmΔ were transfected respectively followed by 
treatment with proteasome and lysosome inhibitors. Cells were harvested after 12-hour 
incubation and were analyzed for α-HA and α-GAPDH. Normalized protein level 
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Figure 19. Cycloheximide-chase analysis of IFITM3 turnover. HeLa IFITM2/3 -/- cells 
were plated into 12-well plates before transfection. pCMV-HA-IFITM3 WT, C72A, and 
PalmΔ were transfected respectively and were treated with cycloheximide (CHX) after 18 
hours. Cells were harvested at indicated hours and were analyzed for immunoblotting α-
HA and α-GAPDH. Cycloheximide is an inhibitor of protein biosynthesis in eukaryotic 
organisms, produced by the bacterium Streptomyces griseus. Due to the inhibition of 
overall protein synthesis, by measuring the degradation rate of existing IFITM3 proteins, 
we can measure the half-life of each construct. 
 
Table 6. Rate constant and half-life of CHX chase experiment. 
 WT C72A PalmΔ 
K (hr-1) ~ 7.857e-
005 
0.1643 0.03655 
Half-Life (hr) ~ 22 4.22 18.97 
 
  
56 
 
 
Figure 20. Determination of rate constant and protein degradation half-life. Data of 
cycloheximide chase experiments Triplicates of the degradation experiments were 
performed and the normalized data was fit with one phase decay model using GraphPad 
Prism.  
Triplicates of the cycloheximide chase experiments were fitted with the non-linear 
curve model. Best-fit values of the curve showed that WT IFITM3 was relatively stable at 
half-life of ~22 hours, while the half-life of C72A mutant is 4.22 hours and PalmΔ 18.97 
hours. The rate of protein degradation of IFITM3 was increased to ~5-fold with C72A 
mutation. Interestingly, PalmΔ IFITM3 with three Cys residues mutated is relatively more 
stable than C72A, which is consistent with the western blotting data (Figure 10). The loss 
of stability associated with Cys72 mutation also partly contributed to the lower antiviral 
activity of this construct compared to other Cys mutants during the antiviral assay (Figure 
16). We then want to understand the mechanism of action of how IFIITM3 is degraded and 
why C72 is essential to keep IFITM3 stable. 
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2.3.6 Effects of protein degradation pathway inhibitors 
To understand which degradation pathway was responsible for IFITM3 degradation, we 
used specific inhibitors of proteasome, lysosomal protease and p97 to measure the 
dynamics under those inhibitor treatments. Similar to cycloheximide-chase experiment, 
HeLa IFITM2/3 -/- cells were transfected with IFITM3 C72A construct and were treated 
the CHX and respective inhibitors for designated hours (Figure 21). After immunoblotting 
with α-HA and α-GAPDH, protein expression level was then normalized to plot on the 
non-linear model. 
 
Figure 21. Cycloheximide with inhibitors chase experiment. HeLa IFITM2/3 -/- cells 
were transfected with IFITM3 C72A and were treated with CHX plus proteasome 
(MG132), lysosome (E/P), or p97 (ML240) inhibitors. Cells were harvested at indicated 
time points and snap-freezed. Samples were analyzed by immunoblotting of α-HA 
antibody and α-GAPDH antibody. Cells were mostly dead after 24 hr incubation with 
CHX+MG132 or E/P. CHX+ML240 was much more toxic to cells as most cells were dead 
after 8 hours.   
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 Because of the toxicity of cycloheximide with degradation inhibitors, most cells 
died after 12 hours, especially for CHX plus ML240 samples. So I only use the data from 
the first 12 hours. After plotting with Graphpad Prism, we were able to get the half-life of 
inhibitor-treated samples (Table 7). Interestingly, all three inhibitors increased the stability 
of IFITM3, with ML240 having the most effect. The half-life of C72 was increased from 
4.22 hours to 7.95, 6.38, and 20.26 hours respectively. Since p97/VCP is involved in both 
endosome-lysosome membrane fusion and proteasome degradation pathway, the 
prominent effect of p97 inhibition might suggest that IFITM3 is degraded through both 
proteasome and lysosomal pathway. 
 
Figure 22. Analysis of protein degradation with inhibitors. Triplicates of the 
degradation experiments were performed and the normalized data was fit with one phase 
decay model using GraphPad Prism. 
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Table 7. Determination of rate constant using one phase decay model. 
 CHX+MG132 CHX+E/P CHX+ML240* 
K (hr-1) 0.08723 0.1086 ~ 0.03421 
Half Life (hr) 7.946 6.381 ~ 20.26 
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2.4 Discussion 
2.4.1 Key sites of human IFITM3 S-fatty-acylation 
Bioinformatics analysis of IFITM isoforms from 27 vertebrate genomes representing from 
diverse animals (reptiles, amphibian, fish, birds, primates and other mammals) shows that 
these three S-fatty-acylated Cys residues (C71, 72 and 105 in mIFITM3) are amongst the 
most highly conserved amino acids within this family of membrane proteins (Figure 8) 
(Hickford et al., 2012; Zhang et al., 2012). All three Cys residues of IFITM3 are S-
palmitoylated, APE and alk-16 experiment showed that endogenous IFITM3 is mostly S-
fatty-acylated in IFN-stimulated cells and that S-fatty acylation of specific Cys residues 
and levels are crucial for IFITM3 antiviral activity against influenza virus. In murine and 
human IFITM3, even though Cys71 is highly conserved this residue is dispensable for 
dual-S-fatty acylation and antiviral activity. In contrast, Cys72 in IFITM3 is the most 
prominent site of S-fatty-acylation and results in the loss of antiviral activity when mutated 
to Ala. The S-fatty-acylation and antiviral activity of Cys105 may depend on the IFITM 
isoform, expression levels, and cell-type, as the mutation of this Cys residue decreases 
murine IFITM3 antiviral activity but is not required for human IFITM3 activity. From 
CHX chase experiments, C72A and PalmΔ mutants dramatically decreased protein 
stability of IFITM3, while protein degradation inhibitors restored some but not all of C72A 
stability. In summary, antiviral activity results from our laboratory and others (John et al., 
2013; Yount et al., 2010), S-fatty-acylation assay, and protein turnover experiments 
suggests Cys72 in IFITM3, at the edge of the first helical domain, plays a critical role in 
IFITM3 function. 
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 Protein hydrophobicity analysis using Kyte & Doolittle plot with nine amino acids 
as a window shows that IFITM3 protein contains two major hydrophobic regions. 
Experimental results with in vitro recombinant expression of IFITM3 without S-
palmitoylation also showed insolubility without detergent solubilization. So without 
lipidation IFITM3 is also intrinsic membrane protein. However, ultracentrifugation 
experiment showed there is a higher percentage of IFITM3 PalmΔ in soluble fraction 
compared to IFITM3 wide type purified from mammalian cell lysate, indicating an 
enhanced membrane attachment ability with S-palmitoylation. Indeed, multiple other 
membrane proteins are also S-palmitoylated at the same time such as Calnexin, GPCRs. 
The reasons for such addition lipidation are multi-fold. First of all, attachment of palmitate 
acids increases the membrane affinity of the membrane protein. Secondly, S-
palmitoylation in many cases specifies the membrane subdomain to which modified 
proteins are localized. 
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2.4.2 Lipid composition of IFITM3 S-fatty-acylation 
A key drawback of chemical reporter labeling method is its inability to distinguish the fatty 
acid species that are incorporated into the candidate proteins. Although palmitate is the 
major modification, other long chain fatty acids like palmitoleate, stearate, oleate, 
arachidonate, and eicosapentaenoic acid can also modify proteins on cysteine residues 
(Liang et al., 2001). To determine the composition of fatty acids attached to a particular S-
fatty-acylation site, mass spectrometry analysis of intact S-acylated peptides can provide 
direct evidence. It has been shown that at least singly or dually S-palmitoylated peptides 
can be separated by C18 reversed-phase liquid chromatography and sequenced by mass 
spectrometry (Ji et al., 2013). It is important to know about the lipid composition because 
the levels and composition of fatty acids in vivo can determine the strength and specificity 
of immune responses that are essential for host resistance to pathogens and inflammatory 
metabolic diseases such as type 2 diabetes (Stienstra et al., 2012).  
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2.4.3 Protein stability regulated by S-fatty-acylation 
S-fatty-acylation has been implicated in regulating proteins stability in multiple proteins 
(Linder and Deschenes, 2007). For example, the viral membrane glycoprotein of Rous 
sarcoma virus and two G-protein-coupled receptors, the A1 adenosine receptor and the 
chemokine receptor CCR5 showed reduced stability when S-palmitoylation is defective 
(Gao et al., 1999; Percherancier et al., 2001). S-palmitoylation of SNARE complex in S. 
cerevisiae and anthrax-toxin receptor trafficking in mammalian cells protects proteins from 
degradation by preventing their ubiquitination (Abrami et al., 2006; Valdez-Taubas and 
Pelham, 2005) The SNARE complex protein Tlg1 was recently shown to have opposing 
roles of palmitoylation and ubiquitination in regulating its half-life. Tlg1 is an essential 
target-membrane SNARE in S. cerevisiae that mediates the fusion of vesicles with the late 
Golgi compartment (Siniossoglou and Pelham, 2001; Valdez-Taubas and Pelham, 2005). 
 Similarly, IFITM3 was shown to be regulated by ubiquitination and S-
palmitoylation (Yount et al., 2012). Previously ubiquitination was shown to control 
IFITM3’s stability while S-fatty-acylation affects its anti-viral activity but not its protein 
level. From the CHX chase experiments, C72A and PalmΔ dramatically decreased the 
protein half-life of IFITM3 which suggested that S-fatty-acylation, especially, on Cys72 
residue indeed affect IFITM3’s stability. We also observed that the loss of stability 
associated with Cys72Ala was more prominent in A549 cells than HEK 293T cells. Since 
transfection efficiency is much higher in HEK293T cells, more episomal IFITM3 was 
expressed in HEK293T cells than A549 cells, which may cause overwhelming of normal 
protein degradation pathway. 
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 Another point worth noted regarding the methodology used for analyzing protein 
stability is the toxicity with CHX plus protein degradation inhibitors. Cells treated with 
either CHX or protein degradation inhibitors showed less cell death than combined. Cell 
death caused by drugs treatment might interfere with the results. One way to lower the 
toxicity is to use radioactive pulse-chase approach. First, radioactive labeling with (35)S-
methionine is carried out to label newly synthesized proteins (pulse). Subsequently, the 
dynamics of the decay of these proteins is monitored in the absence of labeled amino acids 
over a defined time period (chase). CHX is not needed for this method, thus may reduce 
the cell death rate. A systematic analysis using radioactive pulse-chase with protein 
degradation inhibitor might provide a more conclusive results on the protein degradation 
pathway.  
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2.4.4 Differences between murine and human IFITM3 
The effect about lower protein expression level was only observed in human but 
not murine IFITM3 Cys72Ala mutants, probably because of the differences between two 
species and there is added complicated regulatory mechanism for human IFITM3. 
Sequence alignment of murine and human IFITM3 showed that the central domains are 
highly conserved with overall 66% identity. The amino acids from Ser53 to Ile108 are 
basically same between human and mouse except position 70, where it is Pro in human, 
but Phe in mouse. Proline is sometimes known as "helix breakers" because they disrupt the 
regularity of the α helical backbone conformation. Since Pro is close to Cys71 and Cys72, 
it might be possible that the change from mouse Phe70 to human Pro70 causes disparity 
on Cys72Ala mutation protein stability.  
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2.4.5 Effect of S-fatty-acylation on protein localization 
To understand the functional significance of IFITM3 S-fatty-acylation, we wanted to 
investigate whether the loss of fatty acylation will affect its localization inside the cell. 
Study of mIFITM3 transiently expressed in HeLa cells showed S-fatty-acylation controls 
clustering of IFITM3 in membranes rather than its trafficking to distinct cellular 
compartments (Yount et al., 2010). In another study, single Cys mutation C72A of human 
IFITM3 in A549 cells exhibited a more centralized expression pattern, although no 
colocalization marker was shown in the image (John et al., 2013). Our study on the murine 
and human IFITM3 WT, single Cys mutants, and palmitoylation-deficient mutant in either 
NIH3T3 cells or HeLa cells confirmed the previous observation that WT IFITM3 is 
colocalized with lysosomal marker LAMP1 and partly with Rab5 and Rab7. However, no 
significant effects on protein localization for Cys mutants were observed. The reason for 
no change in localization of Cys mutations might due to the fact that IFITM3 has different 
S-fatty-acylation states inside the cell. Some of them are functional against virus infection 
while the others are relatively inactive. The subtle change of the proper S-fatty-acylated 
species may not obvious among all IFITM3 population. New site-specific lipidation 
methods and imaging in live cells as well as more detailed biophysical methods will be 
required to evaluate how S-fatty-acylation controls IFITM3 antiviral activity. 
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2.5 Materials and methods 
2.5.1 Materials 
E. coli DH5α (Invitrogen) was used for plasmid propagation and isolation. 
Oligonucleotides were obtained from Integrated DNA Technology. Nucleotides were 
synthesized from Integrated DNA Technologies (IDTdna). Plasmid DNA was purified 
using Qiagen Mini and Maxi prep kits. Metabolic chemical reporter (alk-16) and 
fluorescent dye were synthesized in the lab. QuikChange site-directed mutagenesis kit from 
Agilent was used for mutation experiments. HEK293T cells, HeLa cells were obtained 
from ATCC.  
 
2.5.2 Metabolic incorporation of chemical reporters of protein fatty acylation in 
living cells 
Serum-containing complete cell culture medium (DMEM, invitrogen) was replaced with 
cell culture medium, supplemented with 2% charcoal/dextran-filtered FBS. Cells were 
labeled with either DMSO as a solvent control or 20 to 100 µM (final concentration) 
alkyne-fatty acid chemical reporter (Alk-16) for one hour at 37 °C. Cell pellets were then 
lysed with 4% SDS buffer with EDTA-free protease inhibitors and 1μl (250 U) of 
Benzonase (Sigma-Aldrich). Protein concentration was determined using a standard BCA 
assay (Olson and Markwell, 2001). Aliquots of equal amounts of protein (~50 μg) were 
dispensed into 1.5-ml microcentrifuge tubes, and were brought to 44.5 μl with 4% SDS 
buffer with EDTA-free protease inhibitors. 
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2.5.3 Copper(I)-catalyzed alkyne-azide cycloaddition labeling of cell lysates 
5.5 μl click chemistry master mix (1 µl of 5 mM azido-rhodamine in DMSO, 1 µl of 50 
mM TCEP, 2.5 µl of 2 mM TBTA in 1:4 (v/v) DMSO/butanol, 1 µl of 50 mM CuSO4) was 
added of the to the protein sample (44.5 μl) from method 2.5.2, and vortex to mix. Samples 
are incubated for 1 hour at room temperature, followed by a chloroform/methanol 
precipitation of protein to remove unreacted azido-rhodamine by adding the following ice-
cold reagents to each tube: 200 μl methanol, 75 μl chloroform, and 150 μl water. Mixture 
was vortexed and centrifuged for 15 min at 20,000 × g, at 4 °C. The solution in the tube 
was separated into three phases: the clear upper aqueous layer, the pink-colored lower 
organic layer, and a white layer of protein between the two layers. Remove and discard the 
upper aqueous phase, leaving the lower organic phase and the white layer of protein 
between the two layers. 1ml of ice-cold methanol was added to each sample and mix gently, 
causing the protein pellet to sink to the bottom of the tube. Centrifuge 10 min at 20,000 × 
g, 4 °C. All of the liquid was removed by pipetting, being careful not to disturb the pellet 
and then wash the protein pellet by adding 1 ml of ice-cold methanol and inverting the tube. 
Centrifuge 10 min at 20,000 × g, 4 °C. After carefully removing the methanol, the 
remaining methanol was dried by leaving the sample tubes open on the bench for 20 min 
at room temperature. Protein pellets were then dissolved in 50 μl of 4% SDS buffer with 
EDTA-free protease inhibitors to dissolve the protein pellets. 4×LDS sample buffer 
(Invitrogen) and 2-mercaptoethanol were then added and the samples were heated for 5 
min at 95 °C; 20 µL of the sample was loaded per gel lane for separation by SDS-PAGE 
(4−20% Bio-Rad Criterion Tris-HCl gel).  
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2.5.4 Immuno-precipitation using antibody-conjugated resin for click chemistry 
reaction 
Cells were lysed in Brij97 buffer (1% Brij 97, 50 mM TEA, 150 mM NaCl, pH 7.4) and 
protein concentration was determined using the BCA assay. Add 500-1000 mg protein in 
100 uL Brij97 buffer to a dolphin tube. Prewashed -HA-conjugated agarose (Sigma) in 
Brij97 buffer (Use 15 uL Sigma agarose per sample) was added to protein sample and 
incubate over the nutating mixer at 4 °C for 1h. Agarose was spun down for 1 min at 9000x 
g to remove the supernatant. Agarose resin was then washed three times with 500 uL RIPA 
wash buffer (50 mM TEA, 150 mM NaCl, 1% Na-Deoxycholate, 1% Triton X 100, 0.1% 
SDS). Beads were resuspended in 22.5 uL 4% SDS buffer and 2.5 uL click chemistry 
master mix was added to the beads to incubate for 1 h. 4x blue buffer/BME (165 uL blue 
buffer with 35 uL BME) was added after incubation followed by vortexing and boil for 5 
min. Samples were spin down beads and load gel. After running SDS-PAGE, gels were 
imaged by TyphoonTM scanner (GE Healthcare). 
 
2.5.5 Site mutagenesis using QuikChange methods for Cysteine mutants 
Site-directed mutagenesis was done using Agilent QuikChange II Site-Directed 
Mutagenesis Kit (http://www.agilent.com). Primers used in the experiments are  listed 
in Table 8. 
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Table 8. Sequences of primers for site-directed mutagenesis of IFITM3 cysteine 
mutations. 
Primer name Sequence 
mIFITM3-C71A-F acactcttcatgaacttcgcctgcctgggcttcatagc 
mIFITM3-C71A-R gctatgaagcccaggcaggcgaagttcatgaagagtgt 
mIFITM3-C72A-F ctcttcatgaacttctgcgccctgggcttcatagccta 
mIFITM3-C72A-R taggctatgaagcccagggcgcagaagttcatgaagag 
mIFITM3-C105A-F cgcctccactgctaaggccctgaacatcagcacc 
mIFITM3-C105A-R ggtgctgatgttcagggccttagcagtggaggcg 
hIFITM1-C50A-F ccctcttcttgaactgggcctgtctgggcttcatag 
hIFITM1-C50A-R ctatgaagcccagacaggcccagttcaagaagaggg 
hIFITM1-C51A-F cctcttcttgaactggtgcgctctgggcttcatagcattc 
hIFITM1-C51A-R gaatgctatgaagcccagagcgcaccagttcaagaagagg 
hIFITM1-C84A-F cctccaccgccaaggccctgaacatctggg 
hIFITM1-C84A-R cccagatgttcagggccttggcggtggagg 
hIFITM2-C70A-F ccctcttcatgaacaccgcctgcctgggcttcatag 
hIFITM2-C70A-R ctatgaagcccaggcaggcggtgttcatgaagaggg 
hIFITM2-C71A-F ctcttcatgaacacctgcgccctgggcttcatagcatt 
hIFITM2-C71A-R aatgctatgaagcccagggcgcaggtgttcatgaagag 
hIFITM2-C104A-F cctccaccgccaaggccctgaacatctggg 
hIFITM2-C104A-R cccagatgttcagggccttggcggtggagg 
hIFITM3-C71A-F cctcttcatgaaccccgcctgcctgggcttcata 
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hIFITM3-C71A-R tatgaagcccaggcaggcggggttcatgaagagg 
hIFITM3-C72A-F cttcatgaacccctgcgccctgggcttcatagca 
hIFITM3-C72A-R tgctatgaagcccagggcgcaggggttcatgaag 
hIFITM3-C105A-F cctccaccgccaaggccctgaacatctggg 
hIFITM3-C105A-R cccagatgttcagggccttggcggtggagg 
 
2.5.6 Transfection of mammalian cell lines 
Cells were seeded to be 70–90% confluent at transfection. Medium was changed to Opti-
MEM® for transfection. DNA-lipid complexes were made by mixing Lipofectamine® 
Reagent with DNA plasmids in Opti-MEM® Medium. After 10 min incubation, DNA and 
Lipofectamine® 2000 reagent mixture was added to cells for 16 hours and then check for 
expression. 
 
2.5.7 S-fatty-acylation detection using acyl-PEG exchange 
Cell samples were lysed with 4% sodium dodecyl sulfate (SDS, Fischer) in TEA buffer 
(pH 7.3, 50 mM triethanolamine (TEA), 150 mM NaCl) containing 1x protease inhibitor 
cocktail (Roche), 5 mM PMSF (Sigma), 5 mM EDTA (Fischer) and 1500 units/mL 
benzonase (EMD). The protein concentration of the cell lysate was then measured using a 
BCA assay (Thermo), and adjusted to 2 mg/mL with lysis buffer. Typically, 200 µg of total 
protein in 92.5 µL of lysis buffer was treated with 5 µL of 200 mM neutralized tris(2-
carboxyethyl)phosphine (TCEP, Thermo) for final concentration of 10 mM TCEP for 30 
minutes with nutation. N-ethylmaleimide (NEM, Sigma), 2.5 µL from freshly made 1 M 
stock in ethanol, was added for a final concentration of 25 mM and incubated for 2 hours 
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at room temperature. Reductive alkylation of the proteins was then terminated by 
methanol-chloroform-H2O precipitation (4:1.5:3) with sequential addition of methanol 
(400 µL), chloroform (150 µL) and distilled H2O (300 µL) (all pre-chilled on ice). The 
reactions were then mixed by inversion and centrifuged (Centrifuge 5417R, Eppendorf) at 
20,000 g for 5 minutes at 4o C. To pellet the precipitated proteins, the aqueous layer was 
removed, 1 mL of pre-chilled MeOH was added, the eppendorf tube inverted several times 
and centrifuged at 20,000 g for 3 minutes at 4o C. The supernatant was then decanted, and 
the protein pellet washed once more with 800 µL of pre-chilled MeOH, centrifuged again 
and dried using a speed-vacuum (Centrivap Concentrator, Labconco) To ensure complete 
removal of NEM from the protein pellets, the samples were resuspended with 100 µL of 
TEA buffer containing 4% SDS, warmed to 37o C for 10 minutes, briefly (~5 seconds) 
sonicated (Ultrasonic Cleaner, VWR) and subjected to two additional rounds of methanol-
chloroform-H2O precipitations as described above. 
For hydroxylamine (NH2OH) cleavage and mPEG-maleimide alkylation, the 
protein pellet was resuspended in 30 µL TEA buffer containing 4% SDS, 4 mM EDTA and 
treated with 90 µL of 1 M neutralized NH2OH (J.T. Baker) dissolved in TEA buffer pH 
7.3, containing 0.2% Triton X-100 (Fisher) to obtain a final concentration of 0.75 M 
NH2OH. Protease inhibitor cocktail or PMSF should be omitted, as these reagents can 
interfere with the NH2OH reactivity. Control samples not treated with NH2OH were 
diluted in 90 µL TEA buffer with 0.2% Triton X-100. Samples were incubated at room 
temperature for 1 hour with nutation. The samples were then subjected to methanol-
chloroform-H2O precipitation as described above and resuspended in 30 µL TEA buffer 
containing 4% SDS, 4 mM EDTA, warmed to 37o C for 10 minutes and briefly (~5 seconds) 
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sonicated and treated with 90 µL TEA buffer with 0.2% Triton X-100 and 1.33 mM 
methoxypolyethylene glycol-maleimide (mPEG-Mal, 5 or 10 kDa, Sigma) for a final 
concentration of 1 mM mPEG-Mal. Samples were incubated for 2 hours at room 
temperature with nutation before a final methanol-chloroform-H2O precipitation. Dried 
protein pellets were resuspended in 50 µL 1 X Laemmli buffer (BioRad) and then heated 
for 5 minutes at 95o C. Typically, 15 µL of the sample was loaded in 4-20% Criterion-TGX 
Stain Free polyacrylamide gels (Bio-Rad), separated by SDS-PAGE and analyzed by 
western blot. For western blots, primary antibodies used were anti-calnexin (1:2000 
ab22595, Abcam), anti-Pan Ras (1:500, Ras10, Millipore), anti-mouse IFITM3 (1:1000, 
ab15592, Abcam) anti-FLAG (1:1000, F1804, Sigma) anti-HA (1:1000, ab9134, Abcam), 
and HRP-conjugated anti-HA (3F10, Roche). Secondary antibodies used were HRP-
conjugated goat anti-rabbit (DC03L, Calbiochem), and goat-anti-mouse (ab97023, Abcam). 
Protein detection was performed with ECL detection reagent (GE healthcare) on a BioRad 
ChemiDoc MP Imaging System. 
 
2.5.8 Microscopy 
For determination of IFITM3 localization, transfected HeLa cells were fixed with 3.7% 
(w/v) paraformaldehyde, permeabilized with 0.2% (w/v) saponin or 1% (v/v) Tween and 
blocked with 2% (v/v) FBS in PBS. Cells were incubated with individual antibodies for 30 
min in sequence starting with mouse anti-HA (1/1,000, 16B12, Covance), then goat anti-
mouse antibodies conjugated to rhod- amine red (1/1,000, Invitrogen), then rabbit 
antibodies against specific cellular markers or cholera toxin B conjugated to Alexa-488 
(Invitrogen) followed by sec- ondary goat anti-rabbit antibodies conjugated to Alexa-488 
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(1/1,000, Invitrogen). All antibodies were diluted in PBS and 0.2% (w/v) saponin, except 
for cholera toxin B staining in which PBS and 1% (v/v) Tween 20 was used in all steps. 
Antibodies against calreticulin (1/500, ab2907, Abcam), LAMP1 (1/500, ab24170, Abcam), 
EEA1 (1/100, 2411, Cell Signaling) and golgin-97 (1/100, ab33701, Abcam) were used. 
Cells were incubated with TOPRO-3 (1/1,000, Invitrogen) as a final step. 
2.5.9 Infections, fluorescence microscopy, and flow cytometry 
Influenza virus A/PR/8/34 (H1N1) was propagated in 10-day embryonated chicken eggs 
for 40 h at 37° C and titrated using Madin-Darby canine kidney cells. Cells were infected 
at a multiplicity of infection of 2.5 for 6 h before fixation and staining. For Salmonella 
typhimurium infections, strain IR715 was used, and infections were performed as 
previously described (18). For both flow cytometry and microscopy, cells were fixed with 
3.7% paraformaldehyde in PBS for 10 min followed by a 10-min per- meabilization with 
0.2% saponin in PBS and a 10-min blocking step with 2% FBS in PBS. Cells were stained 
using anti-HA anti-antibody (Covance, clone 16B12) directly conjugated to Alexa-488, -
555, or -647 using kits for 100 μg of antibody available from Invitrogen. Anti-NP (Abcam, 
ab20343) was directly conjugated to Alexa-647 using a similar kit. Likewise, anti-myc 
(Clontech, 631206) was conjugated to Alexa-488. All conjugated antibodies were used at 
a 1:200 dilution in 0.2% saponin in PBS for 30 min at room temperature for both 
microscopy and flow cytometry. Anti-calreticulin (Abcam, ab2907) was used at a 1:1000 
dilution followed by a goat anti-rabbit secondary con- jugated to Alexa-488 (Invitrogen). 
TOPRO-3 (Invitrogen) was used at a 1:1000 dilution in PBS for 10 min to stain nuclei as 
a final step in some experiments before glass slide mounting in ProLong Gold Antifade 
Reagent (Invitrogen).  
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Chapter Three: Site-specific incorporation of unnatural amino 
acid into IFITM3 in mammalian cells 
3.1 Summary 
To understand IFITM3 function and regulation in mammalian cells, I explored the site-
specific incorporation of unnatural amino acids (UAAs) using amber codon suppression 
for potential live-cell imaging and protein crosslinking studies. We chose the pyrrolysyl-
tRNA synthetase (PylRS)/Pyl tRNACUA system from Methanosarcina species due to its 
ability to incorporate structurally diverse UAAs. Using this technology, I systematically 
evaluated sites in mouse and human IFITM3 for the incorporation of UAAs. By screening 
amber codon (TAG) mutants, I identified several IFITM3-TAG mutants that showed with 
high expression levels and no truncation products. Notably, both mouse and human 
IFITM3 F8TAG mutant (Phe8 mutated to the amber codon TAG) showed consistent 
expression in mammalian cells. The full length IFITM3 amber codon mutants labeled with 
UAAs were S-fatty-acylated and showed antiviral activity similar to wild type. Notably, 
these IFITM3 amber codon mutants could be site-specifically labeled with lysine analogs 
for bioorthogonal labeling studies in vitro and living cells. Furthermore, we showed that 
IFITM3 amber codon mutants could also be labeled with photo-crosslinkable UAA, 
DiZPK, for site-specific protein crosslinking in living cells. These studies demonstrate 
IFITM3 can be site-specifically labeled with UAAs for potential live cell imaging and 
protein crosslinking studies. 
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3.2 Introduction 
3.2.1 Overview of site-specific protein labeling 
Amber codon suppression technology has enabled the site-specific incorporation of 
unnatural amino acids bearing uniquely reactive functional groups into proteins in yeast 
(Hancock et al., 2010), bacteria (Liu and Schultz, 2010), mammalian cells (Gautier et al., 
2010; Lang et al., 2012; Mukai et al., 2008), and animals (Bianco et al., 2012; Greiss and 
Chin, 2011) via the evolution of orthogonal aminoacyl-tRNA synthetase/tRNA pairs 
(Figure 23). Site-specific labeling of the proteins with unnatural amino acid containing 
unique chemical reactivity has provided scientists with new tools for understanding basic 
biology and drug development (Krall et al., 2015). Notably, the incorporation of unnatural 
amino acids containing bioorthogonal chemical handles and photocrosslinkers are 
providing new opportunities for imaging studies and protein-protein interaction studies, 
respectively. 
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Figure 23. Site-specific incorporation of UAAs using amber codon suppression. 
Orthogonal synthetase and tRNA are introduced to the host cells. After adding unnatural 
amino acids that are compatible with the orthogonal pair but not with endogenous 
machinery, they will be incorporated into specific positions (unique codon, such as amber 
codon). Figure is taken from (Wang et al., 2001). 
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3.2.2 Application of unnatural amino acids for imaging 
The site-specific incorporation of unnatural amino acids enables powerful new approaches 
to control and image proteins of interest at a site-specific level. While genetic fusion of 
fluorescence protein (GFP, RFP) to the protein of interest is the most common method to 
do imaging, because it is easy to implement and has greatly advanced our understanding 
of protein localization and function, GFP fusion may disturb the structure and function of 
the protein and can be only placed at the N- or C- terminus. The size of GFP is ~27 kDa, 
which may be too big for the purpose of protein labeling, and may disturb the structure or 
localization of the fused proteins, especially if the protein has a small size. By using 
unnatural amino acids, we are able to genetically incorporate fluorescent amino acids or 
bioorthogonal amino acids that can ligate with a fluorophore later. With respect to 
established methods for fluorescently labeling proteins, the incorporation of unnatural 
amino acids has minimal perturbations to protein structure and is therefore unlikely to 
interfere with the function and localization of proteins as approaches using fusions or 
tagging can. 
The ability to introduce amino acids with functional side chains combined with 
bioorthogonal chemistry greatly expands available toolbox to study protein structure and 
function (Liu and Schultz, 2010). Progress on discovery and invention of bioorthogonal 
reactions that do not react with natural entities inside the cell but selectively react with each 
other greatly promoted the development of new methods to visualize, identify, and analyze 
different classes of biomolecules (Figure 24) (Prescher and Bertozzi, 2005; Sletten and 
Bertozzi, 2009). The combination of site-specific labeling and bioorthogonal chemistry 
provides new opportunities for precise imaging studies in vitro and in cells. 
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Figure 24. Site-specific protein labeling. To label protein of interest, the first step is to 
incorporate a natural or unnatural amino acid to the intended site of modification. The 
inserted molecule would be chemoselectively reacted with a fluorescent probe, an affinity 
tag, or PTM analog. The resulting molecule can be either visualized by fluorescence 
imaging, analyzed by proteomics or modulated as a “gain/loss of function” (PTM, 
antibody-drug conjugate, or in situ activation). 
The two-step method used by bioorthogonal chemistry involves 1) incorporation of 
unnatural amino acids with tailor-made side chain and 2) bioorthogonal reaction with the 
externally added chemical probe. For the first step, an orthogonal synthetase/tRNA pair is 
required for incorporation. An orthogonal aminoacyl-tRNA synthetase does not recognize 
any endogenous tRNAs in the host cell, but specifically aminoacylates its cognate 
orthogonal tRNA. On the other hand, endogenous aminoacyl-tRNA synthetases do not 
accept an orthogonal tRNA. Translational incorporation of amino acid substrates of the 
orthogonal aminoacyl-tRNA synthetase responses to a blank codon, most commonly the 
amber stop codon. 
One example using unnatural amino acids strategy to investigate previous 
intractable protein is G-protein coupled receptors (GPCRs) (Figure 25). GPCR is a 
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particularly important class of cell-surface receptors that represent targets for more than a 
quarter of all therapeutic drugs (Daggett and Sakmar, 2011). Amber codon suppression 
method allows site-specific labeling of GPCRs with various molecular probes to facilitate 
cell-based studies of protein–protein or protein–ligand interactions and the visualization of 
conformational changes using fluorescence spectroscopy or single-molecule imaging. 
UAAs such as p-benzoyl-L-phenylalanine (BzF), p-acetyl-L-phenylalanine (AcF), and p-
azido-L-phenylalanine (azF) into heterologously were able to be expressed in GPCRs in 
mammalian cells (Grunbeck et al., 2011; Huber et al., 2013; Tian et al., 2013). 
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Figure 25. Using UAA to study GPCR. Amber stop codon (UAG) suppression 
technology has been used to study GPCR functions. HEK293T or HEK293F cells are 
cotransfected with three different plasmids encoding the evolved synthetase gene, the 
suppressor tRNA gene, and the gene encoding the GPCR with an in-frame TAG mutation 
at a desired position. Culturing the transfected cells in the presence of the UAA results in 
protein translation, with suppression of the amber stop codon and site-specific 
incorporation of the UAA at a desired position to give a full-length protein. Figure taken 
from (Huber and Sakmar, 2014) 
Live-cell imaging using amber suppression requires rapid and compatible 
bioorthogonal ligation with fluorophores (Figure 26). CuI-azide-alkyne cycloaddition 
(CuAAC) reaction has a reasonable reaction rate, but the toxicity of CuI makes it hard to 
use this method to label live cells (Figure 26A). To solve this problem, strain-promoted, 
copper-free azide-alkyne cycloaddition was developed to provide alternatives for live-cell 
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imaging. The tagging of azide-containing glycan with cyclooctyne conjugates has been 
explored previously (Figure 26B) (Agard et al., 2004). Strained cycloocynes enabled rapid 
labeling of cell-surface azides for dynamic cell imaging. However, the dynamic rate of 
cyclooctyne-azide ligation is still low with the first generation around 0.0012 M-1S-1. 
Further development of more reactive cyclooctyne compounds includes 
dibenzycycloocynes and biarylazacyclooctynone compounds. Even with these 
modifications, the most reactive version showed rate constants from ~0.1 to 1 M-1S-1. 
Moreover, synthesis of the cyclooctyne probes is demanding and often low-yielding.  
 
Figure 26. Bioorthogonal ligations. A) CuI-azide-alkyne cycloaddition (CuAAC). B) 
Strain-promoted alkyne-azide cycloadditions (SPAAC). C) inverse-electron-demand 
Diels-Alder cycloaddition (IEDDA). 
The recent development of unnatural amino acids bearing components of the 
inverse-electron-demand Diels-Alder cycloaddition (IEDDA) can react exceptional fast 
with fluogenic dyes with second-order rate constants in the range of 102–104 M–1 s–1 (Figure 
26C) (Lang and Chin, 2014). UAAs that contain strained alkene Bicyclo[6.1.0]nonyne-
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lysine and trans-cyclooctene-lysine (BCNK and TCOK) have been incorporated into 
epidermal growth factor receptor (EGFR) to demonstrate the specific labeling. Membrane 
permeable fluogenic dye-tetrazine conjugate is then ligated to the protein for live-cell and 
super-resolution imaging (Uttamapinant et al., 2015). 
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3.2.3 Application of unnatural amino acids for photocrosslinking 
To capture the transient protein interaction inside a complex system, chemical crosslinking 
has been used to covalently bind partners that are close in space. Crosslinking has also been 
utilized to stabilize protein tertiary and quaternary structure (Sinz, 2006), lipidated protein 
interaction (Peng and Hang, 2015) or conjugate an enzyme or tag to purified protein. 
However, it has been challenging to crosslink specific protein in vivo using traditional 
method. The development of photoreactive UAA has enabled us to study specific protein-
protein interactions in mammalian cells (Davis and Chin, 2012). For example, the 
photoreactive UAAs, BzF and azF, enabled the mapping of ligand-binding sites on 
chemokine receptors (CXCR4 and CCR5) and and on the substance P receptor NK1 
(Grunbeck et al., 2011, 2012; Valentin-Hansen et al., 2014). An alkyl diazirine–containing 
unnatural amino acid, DiZPK, developed by Chen lab was introduced site-specifically onto 
HdeA, which in conjunction with gel-based proteomics permitted the substrate-profiling 
of HdeA in E. coli cells under very low pH conditions (Zhang et al., 2011). 
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3.3 Results 
3.3.1 Unnatural amino acids incorporation in IFITM3 
It has not been possible to image IFITM3 trafficking during virus entry, as N- and C-
terminal translational fusions with fluorescent proteins (GFP or mCherry) aggregate in 
lysosomes and are inactive in antiviral assays (unpublished results Hang laboratory). These 
observations have precluded us from live-cell imaging experiments to directly visualize 
whether IFITM3 is recruited to virus-containing vesicles and shuttles this exogenous cargo 
into lysosomes for degradation or exports these particles through exosomes. However, as 
mentioned above, unnatural amino acid introduced by amber codon suppression provides 
a minimal perturbation to the structure of IFITM3 while introducing a bioorthogonal 
handle that is capable of ligation with fluorophore or affinity tag that is specific to the 
protein. As shown in Figure 27, unnatural amino acids with different functionality could 
be made and incorporated into IFITM3. 
 To develop a robust amber codon suppression system for studying IFITM3, we first 
started from screening optimal expression positions for murine IFITM3. I chose sites based 
on several criteria. First, the residue should not affect protein functions, like post-
translational modification, protein-protein interaction or disulfide bond. Second, ideally 
the residue should have similar side chain size to minimize the impact of unnatural amino 
acids on protein folding and structure. We explored amber codon suppression through 
different domains of IFITM3 (N-terminus, IMD-1, cytosolic domain, I/TMD-2 and C-
terminus) and focused on hydrophobic (Leu, Val, Ile) or aromatic amino acids (Phe, Trp). 
As shown in Figure 28A, N-terminal HA-tagged and C-terminal FLAG-tagged IFITM3 
construct was made to detect both N- and C- terminal epitope to make sure full-length 
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IFITM3 was expressed. I then use BocLys (Figure 27) as an initial UAA to test the 
expression profile of different positions (Figure 28). Full length IFITM3 was expressed 
with the addition of BocLys for several TAG mutants. However, truncation products of 
several TAG mutants near C-terminal were observed, highlighting potential limitations for 
site-specific IFITM3 labeling. Nonetheless, several IFITM3 mutants (F8TAG) showed 
very consistent expression that could be used for the future studies. 
 
Figure 27. Unnatural amino acids used for bioorthogonal labeling. ACPK and alk-Pyl 
are used for CuAAC ligation. DiZPK contains photocrosslinkable group which can be used 
for protein interaction proteomics. øp-Pyl contains cyclopropene group which can be used 
to do fast IED-DA reaction. BocLys is used for screening and optimization of amber codon 
positions. 
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Figure 28. Analysis of murine IFITM3 amber codon mutants with BocLys. Upper 
panel, schematic illustration of mouse IFITM3 and amber mutations positions. HA- and 
FLAG-tags were attached to N- and C- terminal of IFITM3 to be able to detect full-length 
version of the protein. Mutations at different positions across the protein were made. Lower 
panel, pyrrolysyl-rRNA synthetase PylRS/tRNACUA pairs from Methanosarcina species 
was transfected along with different amber codon mutation of IFITM3. The residue number 
on the top of the figure indicates the position of amber codon mutation.  
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 Based on the encouraging results with mIFITM3, I evaluated UAA incorporation 
into human IFITM3 constructs. Similar to the criteria for selecting amino acids position for 
mouse version mentioned above, mutations were made across the human IFITM3 (Figure 
29). Each mutation was then transfected into HEK293T cells with or without BocLys. After 
transfection for 18 hours, cells were harvested and lysed. Cell lysates were then 
immunoblotted for α-HA and α-GAPDH. Protein expression level of each mutant was then 
normalized to GAPDH level, and triplicates of the results were plotted in Figure 30. The 
expression level of IFITM3 mutants depends on the position of the amber codon mutation. 
Some positions exhibited much better protein stability (F8, I74, V93, C105) and expression 
level while others barely expressed (V29, S61, L73, K88) (Figure 30).  
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Figure 29. Profiling sites of amber suppression of human IFITM3 using BocLys. We 
screened human IFITM3 amber mutations at different positions to find the optimal position 
to introduction unnatural amino acids for imaging and cross-linking purpose. Each mutant 
was made based on wild type pCMV-HA-IFITM3 plasmid using QuikChange mutagenesis 
kit. Optimized PylRS/tRNACUA with respective IFITM3 mutant were co-transfected into 
HEK293T cells with or without 50 µM BocK. After incubation for about 16 hours, cells 
were harvested and tested for IFITM3 expression using immunoblotting against HA 
epitope. 
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Figure 30. Relative expression level of human IFITM3 expression level. Triplicate 
experiments of human IFITM3 amber codon expression were plotted as bar graph. Varying 
positions displayed significant differences in protein expression. The number on the x-axis 
indicates amber codon mutation position (X to TAG). F8, I76, V93, and C105 were the 
best-expressed TAG mutants among all the positions. 
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3.3.2 Site-specific bioorthogonal labeling of IFITM3 
To determine if IFITM3 amber codon mutants might be suitable for bioorthogonal imaging 
studies, I evaluated the incorporation of azide- and alkyne-containing UAAs (Figure 27). 
Figure 31A describes the initial protocol I used to evaluate bioorthogonal labeling of 
IFITM3 in vitro. Similar to the previous experiments, mIFITM3 F8TAG, F70TAG, 
V93TAG, I122TAG, L135TAG mutants were transfected individually with PylRS-
tRNACUA, with or without alk-Pyl. Cell lysates were then analyzed for HA-mFITM3-
FLAG expression and click chemistry labeling with fluorescent dyes. The in-gel 
fluorescence results showed that only in alk-Pyl positive samples, fluorescence signal 
corresponding to the molecular weight of IFITM3 can be detected. These results showed 
that in vitro fluorescent labeling of IFITM3 amber codon mutants can be achieved, which 
provides important results for future IFITM3 imaging and membrane topology studies. 
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Figure 31. Site-specific bioorthogonal labeling of IFITM3 in vitro. Upper panel, 
IFITM3 amber mutants were transiently transfected into mammalian cells with 
PylRS/tRNA and unnatural amino acids with bioorthogonal handle (alkyne group in this 
case). After incubation, cells were lysed and solubilized to do click chemistry detection 
with azide-fluorophore. Lower panel, mIFITM3 with N-terminal HA tag and C-terminal 
FLAG mutants were tested for alk-Pyl incorporation and az-rho click chemistry. 
Fluorescence signal can only be detected in alk-Pyl positive samples, even though some of 
the constructs showed truncation products. 
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3.3.3 Photo-crosslinking of DiZPK to study IFITM3 interaction partners 
In addition to site-specific fluorescence labeling of IFITM3, we explored the incorporation 
of DiZPK, a photocrosslinkable amino acid that could be used to covalently trap IFITM3-
interacting proteins in mammalian cells. DiZPK contains a diazirine functional group that 
was previously used to photocrosslink and identify client proteins of the chaperone HdeA 
in E. coli (Zhang et al., 2011). Compared to other photo-activatable chemical groups, 
diazirine has better photo-stability than phenyl azide groups and it is more easily and 
efficiently activated with UV light (330 to 370 nm). Figure 32 upper panel shows the 
scheme for photo-crosslinking DiZPK to identify protein-protein interaction partners. After 
DiZPK was incorporated into IFITM3, cells were then radiated under UV lamp at 
wavelength 365 nm to generate active carbene intermediate to covalently trap nearby 
proteins. Lysates were immunoblotted to check for IFITM3 and its crosslinked products. 
Multiple crosslinked IFITM3 products were clearly seen after UV radiation when DiZPK 
was incorporated (Figure 32). These IFITM3 crosslinked products could represent 
homotypic interactions as well as heterotypic interactions with other key cellular regulators. 
These preliminary results suggest DiZPK-labeled IFITM3 could be used to discover and 
validate IFITM3 interacting proteins for future functional studies. 
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Figure 32. Incorporation DiZPK into IFITM3 for photocrosslinking studies. A) Cells 
were transfected with HA-IFITM3 plus PylRS-tRNACUA with DiZPK. After transfection 
for 18 hours, cells were placed in UV chamber with the lamp at 365 nm wavelength for 5 
min. Cells were then lysed and immunoblotted to visualized linked protein complex or 
immunoprecipitated for proteomics study. B) HA-mIFITM3 F8TAG, V29TAG, V45TAG, 
and F70TAG were cotransfected with PylRS-tRNACUA and DiZPK. After UV radiation for 
5 min or no UV as control, cells were lysed and immunoblotted for α-HA and α-GAPDH. 
Compared to the sample with UV induced crosslinking, several more bands higher than 
MW of IFITM3 were seen. 
.  
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3.3.4 Application of UAA in other membrane proteins 
As we were exploring amber codon suppression technology in IFITM3, I also evaluated 
other membrane proteins to assess the generality of this system. I initially analyzed 
caveolin 1 (Cav1) (Dennis J Dietzen et al., 1995), an intramembrane protein involved in 
vesicle trafficking that has similar biochemical features to IFITMs. I generated several 
Cav1 amber codon mutants and evaluated their expression with UAAs. Most of Cav1 
amber codon mutants can express full-length protein, but V16, V52, V130 TAG mutants 
appeared to yield the best full length Cav1 expression. I then performed click chemistry 
ligation with alk-rho, showed that Cav1 can ideally be bioorthogonally labeled by in-gel 
fluorescence analysis (Figure 33). 
 
Figure 33. Incorporation of UAA in Caveolin 1 (Cav1). Mutations of Cav1 were chose 
using criteria mentioned above. HEK293T cells were transfected with Cav1 plasmids and 
PylRS-tRNACUA. ACPK was added during transfection. After transfection, cells lysates 
were click with alk-Rho for visualization. Immunoblotting and in-gel fluorescence were 
performed to determine the protein expression level and fluorescence signal. 
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3.4 Discussion 
3.4.1 Optimization of Amber codon suppression in IFITM3 
To facilitate imaging and protein-protein interaction studies of IFITM3, we developed 
amber codon suppression system in IFITM3. Since the incorporation efficiency of UAAs 
in different residues and proteins can vary, we first needed to systematically profile 
IFITM3 to find optimal positions for amber codon mutation. As mentioned earlier, we 
chose positions according to several criteria. First, the residue should not affect protein 
functions, like post-translational modification, protein-protein interaction or disulfide bond. 
Second, ideally the residue should have similar side chain size to minimize the impact of 
unnatural amino acids on protein folding and structure. 15 and 24 mutations were made on 
mIFITM3 and hIFITM3 respectively. Each mutant was then tested for incorporation of 
UAA. To make sure full-length proteins were made, N- and C- terminus were tagged with 
HA and FLAG. Immunoblotting using α-HA or α-FLAG would reveal whether full-length 
protein is synthesized. 
Interestingly, mIFITM3 amber codon positions larger than 80 showed truncated 
products corresponding to the molecular weight of the protein from first amino acid to 
amber codon (Figure 28). However, hIFITM3 does not show truncation except a few very 
C-terminal mutations (I122, F129, A131). Screening of mouse and human IFITM3 amber 
codon mutants revealed that indeed protein expression level varies from one position to 
another. mIFITM3 F8, V29, V45, F70 and hIFITM3 F8, I76, V93, C105 mutations 
exhibited best expression efficiency (Figure 32 and Figure 30). Especially, F8TAG showed 
great promise for later applications in live-cell imaging and photocrosslinking due to its 
high expression efficiency with multiple kinds of UAAs. 
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3.4.2 Bioorthogonal labeling of IFITM3 amber codon mutants with UAAs 
UAAs with click chemistry handles (ACPK and alk-Pyl) enabled specific bioorthogonal 
labeling (Figure 27). To increase the signal-to-noise ratio of the labeling, alkyne-containing 
UAA was preferred for labeling and azide-conjugated fluorophore or biotin was then use 
to ligate. Preliminary testing of UAA and dye pairs confirmed that alk-Pyl with az-Rho 
(Cy3) had best fluorescent signal-to-noise level. The protocol of click chemistry is similar 
to the ones we used to identify fatty-acylated proteins with chemical reporter alk-16 (Yount 
et al., 2011b). Our experiments with mIFITM3 amber codon mutants confirmed that 
labeled IFITM3 can be specifically ligated to fluorophores in vitro (Figure 31). 
 
3.4.3 Application of amber codon suppression in other membrane proteins 
Due to the encouraging results from IFITM3 UAA incorporation, we seek to generalize the 
method to other S-palmitoylated transmembrane proteins. Amber codon mutations on 
Cav1, CD9, CANX, TLR2 were made and tested for UAA incorporation. However, only 
Cav1 mutants showed successful expression in several positions (Figure 33) and other 
mutations of CD9, CANX or TLR2 were either not expressed or truncated (data not shown). 
Similar to IFITM3, Cav1 is a short intramembrane protein with flexible helical domain. It 
is possible that flexible intramembrane proteins are more susceptible to amber codon 
suppression. Transmembrane proteins like CD9, CANX, TLR2 may need more careful 
analysis of the amber codon position to locate optimal site for incorporation. 
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3.5 Materials and methods 
3.5.1 Materials 
The plasmids of Cav1, CANX, CD9 were obtained from Addgene. Anti-HA-Peroxidase, 
high affinity (clone 3F10) was from Roche life science. Rabbit polyclonal GAPDH 
Antibody (FL-335) was purchased from Santa Cruz Biotechnology.  
 
3.5.2 Site mutagenesis for amber mutants 
Site-directed mutagenesis was done using Agilent QuikChange II Site-Directed 
Mutagenesis Kit (http://www.agilent.com). Primers used in the experiments are listed in 
Table 9. 
Table 9. Sequences of primers for site-directed mutagenesis of amber mutants. 
mIFITM3-F8TAG-F CACACTTCTCAAGCCTAGATCACCGCTGCCAGTG 
mIFITM3-F8TAG-R CACTGGCAGCGGTGATCTAGGCTTGAGAAGTGTG 
mIFITM3-V29TAG-F CAAGGAAGAATATGAGTAGGCTGAGATGGGGGC 
mIFITM3-V29TAG-R GCCCCCATCTCAGCCTACTCATATTCTTCCTTG 
mIFITM3-V45TAG-F GCTTCTGTCAGAACTACTTAGATCAACATGCCCAGAG 
mIFITM3-V45TAG-R CTCTGGGCATGTTGATCTAAGTAGTTCTGACAGAAGC 
mIFITM3-V58TAG-F GTCGGTGCCTGACCATTAGGTCTGGTCCCTGTTC 
mIFITM3-V58TAG-R GAACAGGGACCAGACCTAATGGTCAGGCACCGAC 
mIFITM3-F63TAG-F CATGTGGTCTGGTCCCTGTAGAATACACTCTTCATGAACT 
mIFITM3-F63TAG-R AGTTCATGAAGAGTGTATTCTACAGGGACCAGACCACATG 
mIFITM3-L66TAG-F GTCTGGTCCCTGTTCAATACATAGTTCATGAACTTCTGCTGCCTG 
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mIFITM3-L66TAG-R CAGGCAGCAGAAGTTCATGAACTATGTATTGAACAGGGACCAGAC 
mIFITM3-F67TAG-F TCCCTGTTCAATACACTCTAGATGAACTTCTGCTGCCTGG 
mIFITM3-F67TAG-R CCAGGCAGCAGAAGTTCATCTAGAGTGTATTGAACAGGGA 
mIFITM3-F70TAG-F CTGTTCAATACACTCTTCATGAACTAGTGCTGCCTGGGCT 
mIFITM3-F70TAG-R AGCCCAGGCAGCACTAGTTCATGAAGAGTGTATTGAACAG 
mIFITM3-L73TAG-F CATGAACTTCTGCTGCTAGGGCTTCATAGCCTATG 
mIFITM3-L73TAG-R CATAGGCTATGAAGCCCTAGCAGCAGAAGTTCATG 
mIFITM3-V82TAG-F CCTATGCCTACTCCTAGAAGTCTAGGGATCG 
mIFITM3-V82TAG-R CGATCCCTAGACTTCTAGGAGTAGGCATAGG 
mIFITM3-V93TAG-F GAAGATGGTGGGTGATTAGACTGGAGCCCAGGC 
mIFITM3-V93TAG-R GCCTGGGCTCCAGTCTAATCACCCACCATCTTC 
mIFITM3-L113TAG-F CTGAACATCAGCACCTTGGTCTAGAGCATCCTGATGGTTGTTATC 
mIFITM3-L113TAG-R GATAACAACCATCAGGATGCTCTAGACCAAGGTGCTGATGTTCAG 
mIFITM3-I122TAG-F TCCTGATGGTTGTTATCACCTAGGTTAGTGTCATCATCATTGT 
mIFITM3-I122TAG-R ACAATGATGATGACACTAACCTAGGTGATAACAACCATCAGGA 
mIFITM3-L130TAG-F GTTAGTGTCATCATCATTGTTTAGAACGCTCAAAACCTTCACAC 
mIFITM3-L130TAG-R GTGTGAAGGTTTTGAGCGTTCTAAACAATGATGATGACACTAAC 
mIFITM3-L135TAG-F ATTGTTCTTAACGCTCAAAACTAGCACACTGATTACAAGGATGAC 
mIFITM3-L135TAG-R GTCATCCTTGTAATCAGTGTGCTAGTTTTGAGCGTTAAGAACAAT 
hIfitm3-F8TAG-F CACACTTCTCAAGCCTAGATCACCGCTGCCAGTG 
hIfitm3-F8TAG-R CACTGGCAGCGGTGATCTAGGCTTGAGAAGTGTG 
hIfitm3-V93TAG-F GAAGATGGTGGGTGATTAGACTGGAGCCCAGGC 
hIfitm3-V93TAG-R GCCTGGGCTCCAGTCTAATCACCCACCATCTTC 
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hIfitm3-L135TAG-F ATTGTTCTTAACGCTCAAAACTAGCACACTGATTACAAGGATGAC 
hIfitm3-L135TAG-R GTCATCCTTGTAATCAGTGTGCTAGTTTTGAGCGTTAAGAACAAT 
hIfitm3-I122TAG-F TCCTGATGGTTGTTATCACCTAGGTTAGTGTCATCATCATTGT 
hIfitm3-I122TAG-R ACAATGATGATGACACTAACCTAGGTGATAACAACCATCAGGA 
hIfitm3-I9TAG-F CACTTCTCAAGCCTTCTAGACCGCTGCCAGTGGAG 
hIfitm3-I9TAG-R CTCCACTGGCAGCGGTCTAGAAGGCTTGAGAAGTG 
hIfitm3-T10TAG-F CTTCTCAAGCCTTCATCTAGGCTGCCAGTGGAGGAC 
hIfitm3-T10TAG-R GTCCTCCACTGGCAGCCTAGATGAAGGCTTGAGAAG 
hIfitm3-N131TAG-F GTGTCATCATCATTGTTCTTTAGGCTCAAAACCTTCACACTG 
hIfitm3-N131TAG-R CAGTGTGAAGGTTTTGAGCCTAAAGAACAATGATGATGACAC 
hIfitm3-S13TAG-F CAAGCCTTCATCACCGCTGCCTAGGGAGGACAGCCCCCAAACTAC 
hIfitm3-S13TAG-R GTAGTTTGGGGGCTGTCCTCCCTAGGCAGCGGTGATGAAGGCTTG 
Cav1-V16TAG-F GGACATCTCTACACCTAGCCCATCCGGGAACAG 
Cav1-V16TAG-R CTGTTCCCGGATGGGCTAGGTGTAGAGATGTCC 
Cav1-V52TAG-F GAGATCGACCTGTAGAACCGCGACCCTC 
Cav1-V52TAG-R GAGGGTCGCGGTTCTACAGGTCGATCTC 
Cav1-V71TAG-F CGCATTGACTTTGAAGATTAGATTGCAGAACCAGAAG 
Cav1-V71TAG-R CTTCTGGTTCTGCAATCTAATCTTCAAAGTCAATGCG 
Cav1-V94TAG-F CAGCTTCACCACCTTCACTTAGACGCGCTACTGGTTTTAC 
Cav1-V94TAG-R GTAAAACCAGTAGCGCGTCTAAGTGAAGGTGGTGAAGCTG 
Cav1-L122TAG-F GGCATTTACTTCGCCATTTAGTCTTTCCTGCACATCTGG 
Cav1-L122TAG-R CCAGATGTGCAGGAAAGACTAAATGGCGAAGTAAATGCC 
Cav1-V130TAG-F CCTGCACATCTGGGCATAGGTACCATGCATTCGC 
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Cav1-V130TAG-R GCGAATGCATGGTACCTATGCCCAGATGTGCAGG 
Cav1-V155TAG-F CCATCTACGTCCACACCTAGTGTGACCCACTCTTTG 
Cav1-V155TAG-R CAAAGAGTGGGTCACACTAGGTGTGGACGTAGATGG 
Cav1-V163TAG-F GACCCACTCTTTGAAGCTTAGGGGCGCATATTCAGCAATG 
Cav1-V163TAG-R CATTGCTGAATATGCGCCCCTAAGCTTCAAAGAGTGGGTC 
 
3.5.3 Unnatural amino acids incorporation in mammalian cell culture 
HEK293T cells were seeded into Corning 6-well plate (Costar, Corning) and grown to 90% 
confluence in 10% fetal bovine serum DMEM (Invitrogen) in a humidified atmosphere of 
5% CO2. Plasmids encoding RNA synthetase and tRNA, pCMV-Mb-DiZPK-RS, were 
obtained from Dr. Peng Chen lab (Zhang et al., 2011). When cells reached 80-90% 
confluency, the media was exchanged to Opti-MEM containing 50 μM unnatural amino 
acids (e.g. BocK), and cells were then transfected with pCMV-Mb-DiZPK-RS and pCMV-
IFITM3 amber mutants using Lipofectamine® 2000 from Invitrogen. Cells were grown for 
an additional 12 h before being visualized by a fluorescence microscope. 
 
3.5.4 In-gel fluorescence detection of ligated products 
Cells were lysed in Brij97 buffer (1% Brij 97, 50 mM TEA, 150 mM NaCl, pH 7.4) and 
protein concentration was quantified with BCA assay. 500-1000 mg protein was aliquoted 
into 100 uL Brij97 buffer in a dolphin tube. Prewashed α-HA-conjugated agarose (Sigma) 
in Brij97 buffer (Use 15 uL Sigma agarose per sample) was added to protein sample and 
incubated over the nutating mixer at 4 °C for 1h. Agarose beads were spun down for 1 min 
at 9000x g. Agarose resin was washed three times with 500 uL RIPA wash buffer (50 mM 
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TEA, 150 mM NaCl, 1% Na-Deoxycholate, 1% Triton X 100, 0.1% SDS). Beads was 
resuspended in 22.5 uL 4% SDS buffer and added to 2.5 uL click chemistry master mix for 
one hour incubation. 4x blue buffer/BME (165 uL blue buffer with 35 uL BME) was added 
for SDS-PAGE. After running SDS-PAGE, gels were imaged by TyphoonTM scanner (GE 
Healthcare). 
 
3.5.5 UV-induced photo-crosslinking by DiZPK 
Photocrosslinking was performed by irradiation of the mammalian cells with UV light (365 
nm) for 0–10 min using a Hoefer UVC 500 Crosslinker installed with 365-nm-wavelength 
UV lamps (Amersham Biosciences) at a distance of 3 cm at 25 °C. The cells were harvested 
by Trypsin digestion and centrifuge at 6000g for 2 min and then analyzed by tricine SDS-
PAGE and immunoblotting with antibodies against the specified proteins. Gel bands and 
western blots were scanned and quantified using the ImageJ program (NIH).  
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Chapter Four: Conclusion and perspective 
4.1 Conclusion 
New chemical methods for protein fatty-acylation have expanded the number of modified 
proteins in eukaryotes and highlighted novel roles in biology (Peng et al., 2016) (Chapter 
1). Indeed, the discovery of IFITM3 S-palmitoylation by the Hang laboratory identified a 
new role for protein fatty-acylation in host resistance to virus infection (Yount et al., 2010, 
2012). Nonetheless, the precise mechanism of IFITM3 antiviral activity and regulation by 
S-palmitoylation is not fully understood. To address these outstanding questions of IFITM3 
function, I characterized endogenous levels and specific sites of IFITM3 S-palmitoylation 
in Chapter 2. I demonstrated that IFITM3 is primarily S-palmitoylated on C72, a highly 
conserved amino acid, which is important for IFITM3 antiviral activity. My additional 
experiments showed that loss of IFITM3 S-palmitoylation, particularly at Cys72, resulted 
in enhanced protein turnover through proteasome- and lysosome-mediated degradation 
pathways. 
 I also developed new chemical tools and expression systems to explore IFITM3 
function and regulation. In particular, I identified IFITM3 amber codon mutants that could 
be used for site-specific labeling with unnatural amino acids. The ability to incorporate 
unnatural amino acids into IFITM3 is providing our laboratory new opportunities for live 
cell imaging studies and photocrosslinking studies, which I will summarize below. In 
addition, I also explored expression and purification of recombinant IFITM3 in bacteria 
for in vitro site-specific lipidation, which may enable reconstitution of IFITM3 in vitro for 
more precise biochemical and biophysical studies. An updated working model for IFITM3 
antiviral activity and future directions is summarized below.  
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4.2 Perspectives 
4.2.1 A model for IFITM3 antiviral mechanism 
IFITMs are important IFN-stimulated effectors that control host susceptibility to many 
viruses, but their mechanisms of action are not understood. Although the complexity of 
IFITMs antiviral mechanism and the specificity of virus inhibition, there are some 
proposed mechanisms for IFITMs activity. In the absence of IFITM3, incoming influenza 
virus particles traffic to acidic endosomes and fuse with host membranes to deposit viral 
RNA for infection. In IFN-stimulated cells, expression of IFITM3 inhibits virus entry and 
may divert incoming virus particles for degradation in lysosomes. 
IFITM3 does not appear to block the internalization of viruses such as VSV, 
influenza virus or HCV into host cells but instead prevents deposition of viral contents into 
the cytosol (Feeley et al., 2011; Huang et al., 2011; Schoggins et al., 2011; Weidner et al., 
2010). Additional cell biology studies have suggested that IFITM3, localized to endocytic 
vesicles and lysosomes, may directly block virus pore formation  or indirectly inhibit virus 
entry by increasing vesicular cholesterol levels and ultimately target incoming viral 
particles for lysosomal degradation (Amini-Bavil-Olyaee et al., 2013; Desai et al., 2014; 
Feeley et al., 2011; Li et al., 2013). More recent studies have suggested that IFITM3 does 
not affect virus-host membrane hemifusion but impairs pore formation or alter lipid vesicle 
composition (Amini-Bavil-Olyaee et al., 2013; Desai et al., 2014). The localization of 
IFITM3 on vesicles has even been proposed to alter membrane curvature and generate 
“tough membranes” to inhibit virus membrane fusion (Perreira et al., 2013). Beyond 
viruses, IFITMs have been recently reported to restrict Mycobacterium tuberculosis 
infection (Ranjbar et al., 2015). 
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Figure 34. IFITM3 antiviral working models. Incoming viruses are first trapped into 
early endosome (marker protein Rab5) where some of the IFITM3 population colocalize. 
As vesicles mature to late endosomes, IFITM3 will first enhance the membrane rigidness 
to prevent back fusion into the cytosol and secondly direct vesicles into a non-productive 
pathway for degradation, like lysosome. Immunofluorescence showed IFITM3 strongly 
colocalized with lysosome marker LAMP1 indicating its role as vesicular trafficking factor 
for the virus to degrade in the lysosome. 
 Recent studies in our laboratory suggests that IFITM3 may act like “immune-
SNAREs” for pathogens due to its interaction with syntaxin proteins (Q-SNARE) and 
similarity with VAMP proteins (R-SNARE). VAMPs with similar size to IFITMs are also 
S-fatty-acylated (unpublished data). Knockdown of VAMPs increased susceptibility to 
virus infection and are essential for vesicle fusion (Pirooz et al., 2014). VAMPs may thus 
serve as models to understand how IFITM3 directs pathogen-containing vesicles into 
degradative cellular compartments. The new chemical tools developed in my thesis studies 
may help understand IFITM3 mechanism and regulation by S-fatty-acylation.  
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4.2.2 Future studies  
Live-cell imaging to monitor IFITM3 trafficking 
The amber codon suppression technology developed for IFITM3 is providing a new system 
for live-cell imaging (Figure 35). To profile different cell permeable fluorophores, 
rhodamine, BODIPY or Si-rhodamine (Lukinavičius et al., 2013) were synthesized and 
tested for three amino acids. Human IFITM3-F8TAG amber mutant was used as a model 
protein because the previous study had shown that UAA can robustly incorporate into 
F8TAG mutant. Si-Rho with TCOK showed strong and specific bioorthogonal labeling 
(Figure 36). The biocompatible near-infrared high permeability and fluorogenic character 
permit the imaging of proteins in living cells and tissues without washing steps, and its 
brightness and photostability make it ideally suited for live-cell super-resolution 
microscopy (Lukinavičius et al., 2013). 
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Figure 35. Scheme of site-specific live cell imaging using IED-DA reaction. Amber 
suppression-mediated incorporation of øp-Lys in IFITM3-TAG mutants enables 
bioorthogonal ligation with tetrazine-dyes for in-gel fluorescence profiling of cell lysates 
and live cell labeling for confocal fluorescence imaging studies. 
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Figure 36. Screening for an optimal pair of unnatural amino acids and tetrazine dye. 
Several UAAs, øp-Lys, BCNK and TCOK were tested individually with multiple kinds of 
fluorescent tetrazine dye to screen the optimal pair for labeling IFITM3-F8TAG. Artificial 
units were used to indicate the relative labeling intensity of each pair. Data from Tao Peng. 
Live-cell imaging experiments were then performed using the optimal conditions 
(Figure 37). IFITM3-F8TAG labeled with Si-Rh-Tz colocalized very well with GFP-
LAMP1, which is consistent with the immunofluorescence results. α-HA 
immunofluorescence of HA-IFITM3 overlapped very well with the Rhodamine 
fluorescence, which further confirmed the specificity of the UAA labeling. This new 
technology provides us an exciting opportunity to image IFITM3 trafficking in living cells 
during virus infection for the first time. We will optimize the multiplicity and kinetics of 
fluorophore-labeled IAV and then perform live cell imaging studies in IFITM2/3-KO cells 
coexpressing Si-Rh-Tz-labeled IFITM3 and other GFP-labeled cellular markers. By 
monitoring the time-lapse imaging of IAV particle infection process, we would be able to 
know at what step do IFITM3 engages the virus-containing vesicle and the degradation 
109 
 
process. To further understand the specificity of IFITM3 cargo selectivity, other 
fluorescently-labeled exogenous cargo such as dextran, transferrin, EGF will be tested in 
parallel with IAV assay. 
 
Figure 37. Live cell imaging of IFITM3 F8TAG with Si-Rh-Tz. Upper panel, Si-Rh-Tz 
labeled IFITM3-F8TAG were cotransfected with GFP-LAMP1. Live-cell imaging were 
then performed and in consistent with previous observation, Rhodamine signal overlap 
very well with GFP-LAMP1. Lower panel, pH sensitive EGF-pHrodo® Green is used for 
the detection of internalized EGF receptor in cells. Data from Tao Peng. 
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Understanding IFITM3 membrane topology with UAA accessibility methods 
The membrane topology of IFITM3 was predicted to be dual transmembrane protein but 
the identification of K24 ubiquitination on mouse IFITM3 raised the possibility that the 
predicted dual-pass transmembrane topology was incorrect since the enzymes responsible 
for ubiquitin conjugation are localized in the mammalian cytosol (Brass et al., 2009; Yount 
et al., 2012). To further support the N-terminal cytosolic orientation, phosphorylation of 
Tyr20 has also been reported to regulate IFITM3 endocytosis from the plasma membrane 
(Chesarino et al., 2014a; Jia et al., 2014). Subsequent N-linked glycosylation mapping 
studies and protein lipidation site engineering (N-myristoylation and C-prenylation) 
studies suggest that mIFITM3 may be an intramembrane protein where both the N- and C-
termini of mIFITM3 have access to the cytoplasm (Yount et al., 2012). More recent 
epitope-mapping studies have also confirmed the cytoplasmic orientation of IFITM3 N-
terminus and also suggest that the C-terminus may either be luminal or extracellular (Bailey 
et al., 2013; Weston et al., 2014). Since multiple UAA positions of IFITM3 are available, 
it creates a new opportunity to study IFITM3 topology with accessibility assay. Basically, 
membrane impermeable fluorophore conjugates could be used to screen IFITM3 with 
amber codons at different positions. Only positions that are outside the vesicle membrane 
should be able to be ligated to the fluorophore. It is especially interesting to figure out 
whether C-terminus of IFITM3 is luminal or cytosolic or a mix of both (Figure 7). 
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Identification of cellular factors required for IFITM3 antiviral activity 
Development of novel tools to study essential proteins or lipids required for IFITM3 
function is vital for us to understand IFITM3 biology. It requires a detailed characterization 
of lipids and proteins in IFITM3-vesicles, which could provide experimental evidence for 
two potential mechanisms of action for IFITM3: 1) vesicle-coating protein that enhances 
membrane integrity by remodeling the lipid or protein composition and or 2) membrane 
trafficking receptor or adapter that sorts virus-containing vesicles to lysosomes for 
degradation or export. 
 As discussed earlier in Chapter 2, the composition of lipids that modify IFITM3 is 
not known. To characterize IFITM3-associated lipids, IFN-stimulated cells will be 
mechanically lysed without detergents by Dounce homogenization and IFITM3-vesicles 
will be purified by α-IFITM3 antibody-conjugated magnetic beads and selectively eluted 
with low pH buffer. Western blot analysis of these purified vesicles will be performed with 
antibodies to IFITM3, endocytic markers, and other organelles to ensure specific and 
efficient enrichment. The immune-purified IFITM3-vesicles will then be extracted with 
chloroform/methanol, concentrated and analyzed by high-performance thin layer 
chromatography (HPTLC) and LC-MS/MS along with commercially available lipid 
standards as previously described (Maeda et al., 2014) 
 It is often challenging to identify the protein-protein interaction between membrane 
proteins due to normal co-immunoprecipitions conditions would perturb the cellular lipid 
environment that is required for proper protein interaction. Amber codon suppression 
coupled with crosslinkable UAA provides a feasible system for capturing this transient 
interaction. 
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To understand the proteins that are interacting with IFITM3 at the N-terminus. Double 
SILAC experiment was performed by our lab. Stable isotope labeling by amino acids in 
cell culture (SILAC) is a simple and straightforward approach for in vivo incorporation of 
a label into proteins for mass spectrometry (MS)-based quantitative proteomics. By 
employing quantitative method, several interesting protein partners were identified such as 
p97/VCP. 
 
Figure 38. Summary of HA-IFITM3-F8-DiZPK double-SILAC X-proteomics. HeLa 
cells labeled with heavy- or light-isotope amino acids plus DiZPK, were tranfected with 
HA-IFITM3-Phe8-TAG, subjected to 5 min of UV-crosslinking or not, combined in a 1:1 
ratio, subjected to anti-HA immunoprecipitation and then analyzed by LC-MS/MS 
sequencing using Orbitrap and MaxQuant. For double-SILAC analysis, DiZPK labeling 
was done with heavy amino acids (Forward) and subsequently performed with light amino 
acids (Reverse). Quantitative comparison of the samples from forward and reverse (H/L) 
ratios reveals protein candidates (i.e. p62) that were robustly photocrosslinked to HA-
IFITM3-Phe8-DiZPK. Data from Tao Peng.  
p62 
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Reconstitute and analyze lipidated IFITM3 in vitro 
Reconstitution of IFITM3 antiviral activity using purified proteins and lipids would 
definitively clarify how IFITM3 works and whether it needs help from other factors. After 
purifying IFITM3 from bacteria, lipidated or unmodified IFITM3 will be incorporated into 
synthetic liposome with different compositions to optimize the best system for IFITM3 
vesicles. Membrane fractionation experiment would be helpful to understand how S-fatty-
acylation changes protein hydrophobicity and lipid preference. Further analysis of how and 
where IFITM3 participate in the membrane fraction by fluorescent tracking using UAA 
labeling of IFITM3 and well-established fluorescent membrane probes would provide 
information on whether S-acylated IFITM3 would prefer ordered membrane fraction. 
 Several studies have been done on loss of function analysis of IFITM3 S-fatty-
acylation through mutagenesis. However, to understand how alterations in S-fatty-
acylation controls IFITM3 targeting to membranes and antiviral activity, we need to 
reconstitute and characterize lipidated IFITM3 in vitro and in vivo. We have successfully 
purified codon optimized mouse and human IFITM3 from E. Coli. Since S-fatty-acylation 
machinery is not available in the bacteria, the proteins we’ve purified have no lipidation. 
To understand the interaction of IFITM3 with membranes, we will chemically install fatty 
acid analogs onto the recombinant IFITM3. To introduce defined lipid structures on 
hIFITM3-His6, we have explored a variety of Cys alkylation methods (maleimide coupling, 
haloacetamide alkylation, direct acylation, disulfide exchange (Kim et al., 2014) and thiol-
ene coupling (TEC) (Valkevich et al., 2012)) and have discovered that maleimide-coupling 
affords the most selective and efficient method for chemical labeling of the Cys residues 
of IFITM3 in vitro. Lipidation with hexadecyl maleimide (Mal-C16:0) induces a clear 
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change in purified mouse and human IFITM3 mobility, but not that of IFITM3 palmΔ 
mutation (Figure 39). 
 
Figure 39. In vitro alkylation with hexadecylmaleimide (Mal-C16:0). 30 µL protein (0.16 
mM for mIFITM3 and much lower for hIFITM3) was mixed with 1 µL 500 mM TCEP 
(250 eq.) solution. The solution was shaken at room temperature for 30 mins. 60 μL of a 
20 mM (500 eq.) solution of the hexadecyl maleimide (Mal-C16:0) in DMF or DMF 
control was then added and the reaction shaken at room temperature for another two hours. 
Chloroform-Methanol precipitation was used to stop the reaction and retrieve proteins. 
 Even though the maleimide lipidated product is not a natural lipid linkage, this 
chemical strategy should provide a reasonable approach to generate and reconstitute 
lipidated IFITM3 variants in vitro (Triola et al., 2012). Amber codon mutation could also 
be introduced into IFITM3 for labeling with fluorescent tags that would facilitate the 
imaging or membrane fusion assay. To further understand how site-specific lipidation 
affects IFITM3 function, we can generate proteins with mono-, di- or tri-lipidated isoforms 
to determine if specific cysteine or cysteine combination is required for proper function. 
As we mentioned before Cys72 has been proved to be an important site for S-fatty-
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acylation, putting back lipidation to Cys72 in vitro and in vivo will further improve our 
understand of the function of S-fatty-acylation. 
 To characterize the activity of the IFITM3-liposome system, we will perform 
liposome fusion assay and membrane permeability assay to understand how IFITM3 
affects vesicle fusion and membrane permeability, which have been suggested as two main 
mechanisms of IFITM3 antiviral activity (Bailey et al., 2014). More importantly, it is 
crucial to show that the reconstituted IFITM3-liposome is biologically active. Recent 
studies have shown that exosomes containing IFITM3 can be added to unstimulated cells 
and protect them from Dengue virus infection (Zhu et al., 2014). Thus, we can design 
experiments to compare the antiviral activity of fluorescent lipidated IFITM3-exosomes 
with nonlipidated version. Importantly, the production of active recombinant lipidated-
IFITM3 may provide a well-defined protein-based therapeutic for the prevention or 
treatment of IAV infections in humans with loss-of-function mutations in IFITM3 (Everitt 
et al., 2012; Wang et al., 2013; Zhang et al., 2013b). 
 
Summary 
My thesis work focused to the development of chemical tools to study the innate immune 
protein IFITM3, especially focused on the function of S-palmitoylation. The new tools for 
live-cell imaging, site-specific photocrosslinking and in vitro reconstitution system should 
facilitate future studies on the mechanisms and regulation of IFITM3 antiviral activity. The 
enhanced understanding of IFITM3 not only helps us figure out how IFITM3 restricts a 
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broad spectrum of viruses, but may enable the development of new therapeutic approaches 
against intracellular pathogens in the future.  
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